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9ABSTRACT
Sandler, Charlotta 2005. Mast cells and synovial ﬁ broblasts as novel targets for 
antirheumatic therapy.
Rheumatoid arthritis is a chronic destructive disease of joints associated with severe 
individual suﬀ ering. Despite the recent progress in the treatment of RA, a signiﬁ cant 
proportion of patients fail to respond to the current drug therapy reﬂ ecting the need 
for new drug innovations. In order to develop new therapies for RA, it is essential to 
increase the understanding of the mechanisms that contribute to the disease process. 
Th is study was designed to investigate whether mast cells and synovial ﬁ broblasts could 
serve as novel targets for antirheumatic therapy. 
Proinﬂ ammatory mediators produced by variety of cell types in diseased synovium 
play a central role in the pathogenesis of RA. Mast cells are capable of secreting an 
impressive array of proinﬂ ammatory mediators. Th e results of the present study show 
that selective activation of mast cells in synovial tissue obtained from patients with RA, 
results in a signiﬁ cant production of TNF-α and IL-1β which are the key cytokines in 
the pathogenesis of RA. Th ese results support the previous observations that mast cells 
are involved in the pathogenesis of RA and thereby may provide a novel strategy for 
therapeutic intervention in RA.
Chemically modiﬁ ed tetracyclines (CMTs) are doxycycline derivatives that have 
the anticollagenolytic properties but lack the antibiotic properties of doxycycline. Th e 
results of the present study indicate that CMTs inhibits the cytokine production by 
cultured mast cells. Furthermore, CMT-3 inhibited cytokine production induced by 
IgE-dependent mast cell activation in rheumatoid synovial tissue. Th is inhibition was 
assigned to the observed ability of CMT-3 to inhibit the activity of protein kinase C. 
Finally, the results of the study showed that CMTs induce apoptosis in cultured mast 
cells. 
Imatinib mesylate blocks the function of speciﬁ c tyrosine kinases, including c-kit and 
platelet-derived growth factor (PDGF) receptor. Since signalling through these receptors 
is implicated in RA, this study aimed at investigating the eﬀ ects of imatinib mesylate on 
the viability of mast cells and on the proliferation of synovial ﬁ broblasts. Th e results show 
that imatinib mesylate induced a profound apoptosis in mast cells. Imatinib also inhibited 
signiﬁ cantly the proliferation of synovial ﬁ broblasts which was attributed to its ability 
to prevent PDGF-mediated growth stimulation. Th us, imatinib mesylate represents a 
potential novel approach as it may exert antirheumatic activity by inhibiting mast cell 
activity and proliferation of synovial ﬁ broblasts in rheumatoid synovium. Th e preliminary 
clinical ﬁ ndings on the eﬃ  cacy of imatinib mesylate in the treatment of RA are consistent 
with this conclusion.
In conclusion, synovial mast cells seem to be capable of elaborating a signiﬁ cant 
inﬂ ammatory reaction in rheumatoid synovial tissue. Th e results of the study also 
show that CMT-3 and imatinib mesylate are eﬀ ective inhibitors of mast cell function. 
Th us, these compounds might provide new approaches for the treatment of rheumatoid 
arthritis.
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1. 
INTRODUCTION
Rheumatoid arthritis (RA) is the most common inﬂ ammatory arthritis worldwide, 
with prevalence of 0.8 % in Finland. RA is a systemic inﬂ ammatory disease of 
unknown cause with a central feature of chronic inﬂ ammation in the synovium 
of the joints. Despite the impressive progress in the treatment of RA, the disease 
is associated with severe long-term outcomes and it is a major cause of disability. 
Th e pathogenesis of RA is still incompletely understood despite of intensive 
research. Nevertheless, many processes contributing to the pathogenesis have been 
uncovered. 
RA is a chronic inﬂ ammatory disease. Th e underlying cause of RA is unknown. 
Th e disease is characterised by inﬁ ltration of inﬂ ammatory cells, such as T cells, 
macrophages and mast cells, into the synovium. Th e inﬁ ltrating cells produce 
abundant number of cytokines, such as TNF-α and IL-1β, which stimulate 
further recruitment and activation of inﬂ ammatory cells and resident synovial 
ﬁ broblasts. Th ese interactions lead to chronic inﬂ ammation in the joint, to ﬁ broblast 
hyperproliferation and to formation of an invasive pannus tissue, ultimately resulting 
in the destruction of the joint structures. 
Mast cells are powerful cells of the immune system that reside mainly in 
connective tissue and in mucosal membranes. Upon activation via the high-aﬃ  nity 
IgE-receptors, mast cells secrete a wide array of proinﬂ ammatory mediators, most 
notably histamine, proteases, cytokines and arachidonic acid metabolites. However, 
mature mast cells are activated also via various IgE-independent mechanisms. A 
pathogenic role for mast cells is implicated in many inﬂ ammatory diseases such as 
allergic disorders and asthma. Increasing evidence suggests that mast cells play an 
important role also in chronic inﬂ ammatory disorders.
Recent research ﬁ ndings have strongly indicated that mast cells are involved in 
the pathogenesis of RA. Mast cell hyperplasia is prominent in inﬂ amed synovium. 
Increased mast cell numbers correlate with the activity of the disease. Signs of mast 
cell activation have been detected both in RA synovium and in synovial ﬂ uid from 
patients with RA. However, lack of eﬃ  cient and selective inhibitors of mast cell 
function has hampered the deﬁ nitive clariﬁ cation of the role of mast cells in RA.
Th e treatment of RA has improved signiﬁ cantly during the last decade. Th e 
recommended early and aggressive introduction of disease-modifying antirheumatic 
drugs (DMARDs) has improved the prognosis of new RA patients. Th e anticytokine 
therapies have revolutionised the treatment of severe RA. However, no curative 
treatments are available and a considerable proportion of patients do not respond 
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adequately to the current medications. Th erefore, research contributions are needed 
to ﬁ nd new therapeutic approaches to treat the disease.
Imatinib mesylate is a tyrosine kinase inhibitor with relative selectivity 
towards bcr-abl tyrosine kinase, platelet-derived growth factor receptor (PDGFR) 
tyrosine kinase and c-kit receptor tyrosine kinase. A pilot clinical trial observed 
an antirheumatic eﬀ ect in patients treated with imatinib (Eklund and Joensuu 
2003), which could theoretically be explained by inhibition of mast cells via c-kit 
receptor and inhibition of synovial ﬁ broblasts via PDGFR. Tetracyclines are a group 
of antibiotic agents that might hold therapeutical eﬀ ects in treatment of RA and 
osteoarthritis (Stone et al. 2002). Chemically modiﬁ ed tetracyclines (CMTs) are 
doxycycline derivatives that act anticollagenolytic but lack the antibiotic properties. 
CMT-3 has been studied particularly in treatment of cancers.
In the present study, the role of mast cell activation in rheumatoid synovial 
tissue has been studied. Th e emphasis has been to determine the eﬀ ects of two 
drugs, imatinib mesylate and chemically modiﬁ ed tetracycline-3, on the function 
of cultured and synovial tissue mast cells. In addition, the eﬀ ect of imatinib on the 
proliferation of rheumatoid synovial ﬁ broblasts was studied. Th ese studies aimed at 
ﬁ nding new means to inhibit mast cells and determining whether preventing mast 
cell activity and inhibiting the growth of synovial ﬁ broblasts could serve as new 
approaches for the treatment of RA.
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2.
 REVIEW OF THE LITERATURE
2.1 MAST CELLS
Mast cells are granulated immune cells that are widely distributed throughout the 
body. Th ey are derived from bone marrow progenitor cells that migrate into tissues, 
where they undergo ﬁ nal maturation. Proliferation, diﬀ erentiation, survival and 
activation of human mast cells are regulated by stem cell factor (SCF), the ligand for 
the c-kit tyrosine kinase receptor which is expressed on the mast cell surface. Mast 
cells release a broad array of proinﬂ ammatory and immunoregulatory mediators 
after activation induced by either IgE-dependent or IgE-independent mechanisms. 
Mast cells have been most widely understood in the context of allergic reactions 
and parasite infections, but they are now also acknowledged as important players in 
innate and acquired immunity, wound healing, ﬁ brosis, and chronic inﬂ ammatory 
diseases, such as RA.
2.1.1 Origin and maturation
Mast cells are derived from hematopoietic CD34+ stem cells that originate in bone 
marrow (Kirshenbaum et al. 1991). Mast cell progenitors are agranular mononuclear 
cells that are commited mast cell progenitors i.e. they can not diﬀ erentiate to any 
other cell type (Rodewald et al. 1996). Progenitor cells circulate in peripheral blood 
before entering the tissues where they complete their diﬀ erentiation and maturation 
to mast cells (Li et al. 1999). Circulating mast cell progenitors express c-kit 
receptors and low aﬃ  nity FcγRII-receptors on their surface (Rodewald et al. 1996). 
In opposite to mature mast cells, the progenitor cells do not express high aﬃ  nity 
FcεRI-receptors (Rodewald et al. 1996). Th ese mast cell progenitors represent a 
proportion of 5-15% of total mast cell numbers in tissues, which indicate that mast 
cell progenitors migrate from blood to target tissues at an early stage of maturation 
(Craig et al. 1989).
Th e maturation of mast cells occurs in tissues. Th e key regulators of diﬀ erentiation 
of human mast cells are SCF and its tyrosine kinase receptor c-kit (Valent et al. 
1992, Mitsui et al. 1993, Irani et al. 1992). SCF is an essential factor for both mast 
cell maturation and maintenance of mature mast cells in the body, since it induces 
mast cell proliferation and suppresses mast cell apoptosis (Kirshenbaum et al. 1992, 
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Mekori et al. 1995). Th e critical role of SCF in mast cell maturation is supported by 
the ﬁ ndings that the number of tissue mast cells is greatly decreased in SCF-deﬁ cient 
mice (Sl/Sld) (Kitamura et al. 1978, Huang et al. 1990, Brannan et al. 1991) and 
in mice which lack the functional SCF receptor (W/Wv) (Kitamura and Go 1979, 
Geissler et al. 1988). In tissues, SCF is provided either in a soluble form or membrane-
bound on ﬁ broblasts (Kambe et al. 2001, Hogaboam et al. 1998), stromal cells (Galli 
et al. 1993) or endothelial cells (Mierke et al. 2000). In synovium, SCF is expressed 
by synovial lining cells, stromal ﬁ broblasts, macrophages, endothelial cells, and in 
vascular basement membranes (Ceponis et al. 1998). In addition to regulation of 
mast cell viability, SCF acts as a chemoattractant for mast cells (Meininger et al. 
1992, Kiener et al. 2000).
After the maturation process mast cells express FcεRI-receptors on their cell 
membrane and their cytosol is crowded by secretory granules (Kirshenbaum et al. 
1991). In addition to maturation process of mast cell progenitors, mast cell number 
in tissues can increase due to local proliferation of mature mast cells in response 
to SCF (Kambe et al. 2001, Bischoﬀ  et al. 1999). In brief, mast cell populations in 
tissues are controlled by three diﬀ erent factors: recruitment of committed progenitors 
from circulation, maturation of resident progenitors in tissues, local proliferation of 
mature mast cells and apoptosis of tissue mast cells.
2.1.2 Distribution and heterogeneity
Mast cells are resident cells in tissues throughout the body. Th ey are frequently 
found around blood vessels, in the vicinity of nerves, in the skin and at mucosal 
surfaces both in the airways and the intestine. Th eir location at the interface of 
host and environment reﬂ ects their role in early defence against invading pathogens 
(Metcalfe et al. 1997, Galli et al. 1999, Nathan 2002, Marshall 2004). Mast cells 
are found also in synovial tissue and their number has been shown to be increased 
under inﬂ ammatory conditions (Crisp et al. 1984b, Gotis-Graham and McNeil 
1997). Under normal conditions mature mast cells are not found in peripheral blood 
(Metcalfe et al. 1997).
Mast cell populations are heterogeneous with variability in size, granule contents, 
cytokine production and receptor expression. Two major mast cell types have been 
identiﬁ ed in humans, the TC-type (MCTC) containing both tryptase and chymase, 
and the T-type (MCT) containing only tryptase (Irani et al. 1986, Irani et al. 1989). 
MCTC also contain cathepsin G (Schechter et al. 1990) and carboxypeptidase-A 
(Irani et al. 1991) in their granules. Th e local microenvironment is able to regulate 
the mast cell phenotype (Austen and Boyce 2001). Th e diﬀ erent mast cell subsets are 
found in diﬀ erent locations within human tissues. Furthermore, the distribution of 
mast cell subsets within tissues is altered in diﬀ erent disease stages. 
In addition to SCF, mast cell migration and diﬀ erentiation is inﬂ uenced by 
several locally produced cytokines, such as IL-3 (Rottem et al. 1994, Ochi et 
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al. 1999), IL-4 (Toru et al. 1998, Bischoﬀ  et al. 1999), IL-9 (Ochi et al. 1999) 
and the nerve growth factor (Kanbe et al. 2000). Th e ability of SCF to support 
certain stages of mast cell diﬀ erentiation is profoundly aﬀ ected by interactions with 
other cytokines, particularly IL-4 and IL-10 (Rennick et al. 1995). Th us, the ﬁ nal 
diﬀ erentiation of mast cell progenitors is dependent on the cytokine patterns that 
are present in diﬀ erent microenvironments.
In RA synovium, increased numbers of mast cells are frequently found close to the 
synovial lining layer and around blood vessels. MCTC is the major phenotype in 
healthy human synovial tissue, while expansion of the MCT subset is observed in 
early RA (Gotis-Graham et al. 1998). An increased density of MCT cells have been 
described in late RA synovium, but this was associated with a substantial expansion 
of MCTC cells (Gotis-Graham and McNeil 1997). Generally, it appears that the 
MCT subset is of importance in the inﬂ ammatory events in both early and late 
RA, whereas the MCTC subset may contribute to the repair of damaged connective 
tissue in late RA (Gotis-Graham and McNeil 1997, Gotis-Graham et al. 1998).
Th e two mast cell subsets show functional diﬀ erences. In addition to their 
eﬀ ects on mast cell diﬀ erentiation and maturation, cytokines, such as SCF, IL-4, 
IL-5 and IL-6, can also modify the mediator release (Tkaczyk and Gilﬁ llan 2001). 
MCTC and MCT also express distinct cytokine proﬁ les. MCT have been found to 
produce predominantly IL-5 and IL-6, whereas MCTC in the same tissue produce 
IL-4 only (Bradding et al. 1995). In summary, the microenvironment around the 
mast cell regulates the phenotypic characteristics, receptor expression and the array 
of secreted mediators.
2.1.3 Mast cell activation
A fundamental feature of mast cells is their ability to secrete the contents of preformed 
cytoplasmic secretory granules in response to certain stimulants. Classically, 
crosslinking of the IgE, which is bound to high-aﬃ  nity IgE receptors (FcεRI) 
on mast cells initiates signalling cascades leading to degranulation. Apart from 
activation via FcεRI, mast cells are also activated by cross-linking of surface FcγRI, 
by complement fractions C3a and C5a, by a range of small peptides, including 
substance P, and by chemokines, such as macrophage inﬂ ammatory protein (MIP)-
1α and monocyte chemoattractant peptide (MCP)-1. 
Mature mast cells express FcεRI. Th e receptor is comprised of four subunits, an α 
subunit, a ß subunit and two γ subunits, which form a covalently linked homodimer. 
All the subunits lack intrinsic enzymatic activity. Th e FcεRI α subunit is responsible 
for the high-aﬃ  nity binding of IgE, whereas the primary function of the FcεRI ß 
and FcεRI γ subunits is to recruit signalling molecules into the receptor. Binding 
of a multivalent antigen to FcεRIα/IgE complex provokes the IgE crosslinking and 
leads to aggregation of FcεRI α chains (Blank et al. 1989, Turner and Kinet 1999). 
Th e aggregation of FcεRI initiates the activation of intracellular coupled tyrosine 
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kinases, Lyn and Syk, which leads to phosphorylation of immunoreceptor tyrosine-
based activation motifs (ITAMs) and eventually to activation of diﬀ erent proteins 
and lipids, including phospholipase C isoforms, and protein kinase C (PKC), 
that are implicated in these signalling cascades (Jouvin et al. 1994, Metcalfe et 
al. 1997, Reischl et al. 1999, Turner and Kinet 1999). Th ese cascades couple to 
further downstream steps, such as transient increase in free cytosolic [Ca2+], and to 
additional activation of PKC. Th e signalling events ﬁ nally culminate in the secretory 
response within seconds and minutes after the initial stimulation, and later to the 
production of cytokines. An overview of FcεRI-mediated signalling is presented in 
Figure 1.
Besides IgE-dependent activation, various other mechanisms exist that 
stimulate mast cells to degranulate. Mast cells express receptors for IgG. FcγRIIb 
and FcγRIIIa are low-aﬃ  nity IgG-receptors expressed by mast cells and principally 
involved in the response to immune complexes (Nigrovic and Lee 2005). Following 
interferon (IFN) -γ treatment, human mast cells express also the high-aﬃ  nity 
receptor for IgG, FcγRI (Okayama et al. 2000). Aggregation of these receptors 
in response to antigen binding results in mast cell degranulation. Th e signalling 
pathways activated by FcγRI aggregation generally resemble those activated via 
FcεRI. Also the mediator proﬁ le resembles that observed in human mast cells after 
IgE-dependent degranulation, although there are some diﬀ erences in the proﬁ le of 
cytokine production (reviewed in Tkaczyk et al. 2004).
Figure 1. FcεRI-mediated intracellular signalling in mast cell. A simpliﬁ ed scheme 
of signaling pathways induced by antigen binding to FcεRI (modiﬁ ed from 
Tkaczyk and Gilﬁ llan 2001).
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Th e anaphylatoxic complement peptides C3a and C5a, have long been considered 
as mast cell activators (Metcalfe et al. 1981). However, it appears that only MCTC 
type mast cells express receptors for C3a and C5a, and can subsequently be activated 
by these complement components (Mousli et al. 1994). Synovial mast cells in patients 
with RA represent predominantly MCTC type and they have been shown to express 
C5a receptor and respond to stimulation with C5a (Kiener et al. 1998). 
Mast cells have been found to be activated in various T cell-mediated inﬂ ammatory 
processes. Mast cells reside in close physical proximity to T cells in inﬂ amed allergic 
tissues and at sites of parasitic infections (Mekori and Metcalfe 1999, Mekori and 
Baram 2002). T cells can mediate mast cell activation both by secreting soluble 
cytokines and by direct cell-cell-contact (reviewed in Mekori and Baram 2002). 
Conversely, activated mast cells produce mediators, such as leukotrienes, platelet-
activating factor (PAF), TNF-α and macrophage inﬂ ammatory protein (MIP) -2, 
that aﬀ ect T cell-mediated inﬂ ammatory reactions and recruit T-cells to the site of 
inﬂ ammation (Galli 1993, Biedermann et al. 2000, Ott et al. 2003). Th is interplay 
indicates an important function of mast cells within T cell-mediated inﬂ ammatory 
processes, which are strongly implicated in the pathogenesis of RA.
2.1.4 Mediators derived from mast cells
Mast cell activation has three major outcomes: explosive degranulation, with the 
release of preformed mediators such as proteases and histamine, ensuing generation of 
arachidonic acid derivatives, and in the later phase synthesis and secretion of cytokines 
and chemokines. However, all these events do not necessarily happen always, as certain 
mast cell activators induce only cytokine secretion without preceding degranulation. 
Typically, mast cell mediators have more than one function, and the mediators overlap 
in their biological eﬀ ects. In this chapter, the mast cell mediators are reviewed with a 
special reference to joint inﬂ ammation. Mediators secreted from activated mast cells 
and examples of their physiological functions are listed in Table 1.
Mast cells are the major source of histamine in tissues (Metcalfe et al. 1997). 
Histamine is stored in mast cell secretory granules linked to the carboxyl groups 
of proteins and proteoglycans at acidic pH. Histamine is released within seconds 
after mast cell activation and rapidly metabolized in tissues. Th us, histamine usually 
inﬂ uences events near the site of its release. Histamine H1 and H2 receptors mediate 
the wide-ranging biological activities of histamine. As a potent vasoactive and 
bronchoconstrictive agent, histamine is the central mediator of acute allergic and 
anaphylactic reactions. Histamine might contribute to the pathogenesis of arthritis 
as it stimulates MMP production by chondrocytes and by synovial ﬁ broblasts 
(Zenmyo et al. 1995, Tetlow and Woolley 2002 and 2004). 
Tryptase and chymase are the major proteins in mast cells, which emphasise 
their signiﬁ cance in mast cell function. Up to 30 % of the mast cell granule protein 
may consist of these neutral proteases (Welle 1997). Both mast cell proteases appear 
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to be involved in inﬂ ammatory reactions. Mast-cell-derived tryptase has been shown 
to stimulate ﬁ broblast proliferation (Levi-Schaﬀ er and Piliponsky 2003, Frungieri 
et al. 2005), which is one of the cornerstones in the pathogenesis of RA. Chymase 
converts a precursor of IL-lβ to an active form (Welle 1997). Moreover, mast cell 
tryptase and chymase have been shown to activate in vitro the zymogen forms of the 
matrix metalloproteinases (Gruber et al. 1988a, Saarinen et al. 1994), which is likely 
to play a role in the cartilage destruction associated with RA.
Within minutes after encountering stimuli, mast cells begin to generate lipid 
mediators from cell membrane arachidonic acid (Murakami et al. 1995). Th ese 
include, depending on the circumstances, PGD2, LTC4, LTB4 and platelet-activating 
factor (PAF). LTB4 increases vascular permeability. Mast-cell-derived LTB4 appears 
to be involved in the triggering of T cell migration to the site of inﬂ ammation, 
which might play a role in synovitis (Ott et al. 2003). PGD2 is a vasoactive mediator 
and acts as a chemoattractant for neutrophils (McInnes 2003). However, the PGD2 
metabolite 15-d-PGJ2 is emerging as an anti-inﬂ ammatory mediator (Harris 2002). 
It has been shown to induce synoviocyte apoptosis and to suppress experimental 
arthritis (Kawahito et al. 2000).
Mast cell has the capacity to produce an exceptional wide array of cytokines, 
including TNF-α, TGF-β, GM-CSF, SCF, IL-1, IL-4, IL-6, IL-8, IL-13, IL-16, 
MCP-1 and MIP-2. Th e assortment of produced cytokines depends on the mast 
cell type and stimulus. Mast cells are the only cell type that can store preformed 
TNF-α in granules and release it quickly upon activation (Gordon and Galli 1990). 
Mast cells also produce large amounts of TNF-α in response to activation. TNF-
α is a multifunctional cytokine vitally involved in numerous physiological and 
pathophysiological processes (reviewed in Pfeﬀ er 2003 and in Ghezzi and Cerami 
2004). Th e main function of TNF-α appears to be the promotion of inﬂ ammation. 
TNF-α causes activation and diﬀ erentiation of macrophages and monocytes. 
Moreover, TNF-α promotes inﬂ ammation by inducing the production of other 
cytokines, such as IL-1β, and also MMP and prostaglandins (Dayer et al. 1985). 
TNF-α is a chemotactic molecule (Kharazmi et al. 1988). TNF-α also increases 
vascular permeability and induces upregulation of cellular adhesion molecules 
ICAM-1 (intracellular adhesion molecule) and VCAM-1 (vascular cell adhesion 
molecule) in endothelial cells (Osborn 1990, Walsh et al. 1991). Furthermore, TNF-
α induces production of other chemokines by a variety of cells (Strieter et al. 1989, 
Butler et al. 1995). Th us, TNF-α generates a multidimensional positive signal for 
leukocyte migration to the site of inﬂ ammation. In addition, TNF-α is a potent 
inducer of apoptosis. Th e cytotoxic eﬀ ect is mediated via TRAIL (tumor necrosis 
factor related apoptosis-inducing ligand), which selectively induces apoptosis in a 
variety of tumor cells and transformed cells, but not in most normal cells (Wang 
and El-Deiry 2003). Th e role of TNF-α in the pathogenesis of RA is undisputable 
and is discussed later in this review (see 2.2.2).
lotta 1.indd   18 14.6.2005   15:58:15
19
Table 1.  Mediators released by activated mast cells (modiﬁ ed from Marshall 2004). 
TNF=tumor necrosis factor, VEGF=vascular endothelial factor, FGF=ﬁ broblast growth 
factor, LT=leukotriene, PG=prostaglandin, IL=interleukin, GM-CSF=granulocyte 
macrophage-colony stimulating factor, LIF=leukemia inhibitory factor, IFN=interferon, 
TGF=transforming growth factor, CCL, CXCL=chemokine families
Class Mediators Examples of function
Granule-
associated
 
histamine serotonine alter vascular permeability
heparin and chondroitin sulphate enhance cytokine function and 
angiogenesis
tryptase, chymase, 
carboxypeptidase, and other 
proteases
remodel tissue and recuit effector cells
TNF-α, VEGF, FGF2 recruit effector cells and enhance 
angiogenesis
Lipid-derived LTC4, LTB4, PGD2, PGE2 recruit effector cells regulate immune 
responses promote angiogenesis 
oedema bronchoconstriction
Platelet activating factor enhances angiogenesis, induces 
infl ammation
Cytokines TNF-α IL-1α IL-1β IL-6 IL-18, GM-
CSF, LIF, interferons
induce infl ammation
IL-3, IL-4, IL-5, IL-9, IL-13, IL-15, 
IL-16
T-cell helper 2-type cytokines
IL-12, IFN-γ T-cell helper 1-type cytokines
IL-10 TGF-β VEGF regulate infl ammation and 
angiogenesis
Chemokines CCL 2, CCL3, CCL4, CCL5, CCL11, 
CCL20
recruit effector cells, regulate immune 
responses
CXCL1, CXCL2,CXCL8, CXCL9, 
CXCL10, CXCL11
recruit effector cells, regulate immune 
responses
Others nitric oxide and superoxide 
radicals
bactericidal, proinfl ammatory
antimicrobial peptides bactericidal
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In summary, mast cells are equipped with variety of potent inﬂ ammatory 
mediators. Mediators produced by activated mast cells contribute to inﬂ ammatory 
processes. Mast cells exert also chemotactic signals and promote the recruitment of 
leukocytes to the site of inﬂ ammation.
2.1.5 Mast cells in health and disease
Mast cells have been conserved in evolution, despite of their detrimental role for the 
host in allergic diseases and anaphylaxis, suggesting there have to be beneﬁ ts to the 
host. Th e critical role of mast cells in host defence against bacterial infections has been 
clearly demonstrated (reviewed in Marshall 2004). Th e importance of IgE-mediated 
mast cell activation to the health is incompletely understood. One likely advantage 
of it is the resistance to parasitic diseases (Marshall 2004). Th e appropriate release 
of mediators by mast cells challenged with pathogens has clear protective eﬀ ects to 
the host. However, the excessive or inappropriate release of inﬂ ammatory mediators 
from mast cells causes pathological symptoms in many common diseases.
Th e remarkable variety of proinﬂ ammatory mediators derived from mast cells, 
and the recognition that mast cells release these mediators in response to stimulation 
by many diﬀ erent signals in addition to IgE-mediated stimulation, provides 
theoretical basis to the involvement of mast cells in multiple diseases associated 
with inﬂ ammation. Furthermore, the expansion of local mast cell numbers and the 
evidence of degranulation have been observed in a wide spectrum of pathological 
responses and in a large number of diseases, including asthma (Hart 2001, Robinson 
2004), atherosclerosis (Kaartinen et al. 1998, Lindstedt and Kovanen 2004), ﬁ brosis 
(Gruber 2003, Levi-Schaﬀ er and Piliponsky 2003), autoimmune diseases (Benoist 
and Mathis 2002), and inﬂ ammatory bowel diseases (He 2004). Also mast cell 
neoplasias, including cutaneous and systemic mastocytosis and mast cell leukemia, 
exist (Valent et al. 2005). Mast cells are today also implicated in rheumatoid arthritis, 
which is discussed elsewhere in this review (see chapter 2.3).
Mast cells are implicated in numerous diseases where acute and/or chronic 
inﬂ ammation is known to play a role. Typically, mast cell numbers increase in 
diseased tissues due to augmented migration of mast cell progenitors and/or reduced 
apoptosis of mature tissue mast cells. Th ereby intervention with drugs that inhibit 
mast cell activity or induce apoptosis of mast cells could be potentially beneﬁ cial 
in many common diseases, like allergies, asthma, atherosclerosis and inﬂ ammatory 
arthritis.
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2.2 RHEUMATOID ARTHRITIS
Rheumatoid arthritis is the most common inﬂ ammatory arthritis. RA occurs in 
0.5 –1.0 % of the adult population worldwide, with prevalence of 0.8 % in Finland 
(Kaipiainen-Seppänen and Aho 2000). Th ere is a genetic predisposition of the 
disease, with clearly deﬁ ned involvement of HLA of DR4/DR1 (Stasny 1978). Of an 
unknown reason RA is 2–3 times more common in females than in males (Sangha 
2000). Th e mean age at diagnosis of RA is 59.0 years in Finland (Kaipiainen-
Seppänen and Aho 2000). Th e onset of the disease has moved to older age classes. 
Also the severity of the disease has decreased during the last 20 years. Th e reasons 
for these changes are unknown. Despite the impressive progress in the treatment of 
RA, the disease is still associated with severe long-term outcomes, including declines 
in functional status, increased work disability, and increased mortality (Scott et al. 
1987, Weinblatt 2003, Pincus et al. 2004).
2.2.1 Pathogenesis
RA is a systemic inﬂ ammatory disease of unknown cause. A central feature of RA is 
the chronic inﬂ ammation in the synovium of the joints. Th e disease is characterised by 
a chronic, symmetrical progressive polyarthritis that typically aﬀ ects synovial joints. 
Th e natural history of RA varies from self-limited, nonerosive to severe, destructive 
disease. Th e ﬁ rst symptoms are typically pain, stiﬀ ness and swelling in the small 
joints of ﬁ ngers and toes. RA may have systemic manifestations including fatigue, 
low-grade fever, vasculitis, anemia, osteoporosis, and secondary amyloidosis.
Th e pathogenesis of RA is still incompletely understood despite of intensive 
research. Th e typical pathological changes in synovial membrane of RA patients are 
hyperplasia, increased vascularity and inﬁ ltration of inﬂ ammatory cells. CD4+ T 
cell is the main inﬂ ammatory cell type in inﬂ amed synovium and it is considered as 
the main orchestrator of cell-mediated immune responses. One supposed initiator 
of the inﬂ ammation in RA is an unidentiﬁ ed antigen, which activates CD4+ T 
cells. Th e antigen could be either an exogenous antigen, such as viral protein, or 
an endogenous protein, such as collagen. Antigen-activated CD4+ T cells in turn 
stimulate monocytes, macrophages and synovial ﬁ broblasts to produce cytokines 
and to secrete MMPs. Th e stimulation occurs via direct cell-surface contact or by 
release of soluble mediators. Activated CD4+ T cells can also activate B cells through 
cell-surface signalling to produce immunoglobulins, including rheumatoid factor. 
Th e precise pathogenic role of rheumatoid factor is unknown, but it may involve the 
activation of complement through the formation of immune complexes (reviewed in 
Feldmann 2001 and in Firestein 2003).
Joint damage occurs progressively in patients with RA. Th e proinﬂ ammatory 
cytokines IL-1β and TNF-α play a key role in promoting cartilage and bone 
erosions in the inﬂ amed joint. Th e appearance of structural damage in joints is 
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an indicator of disease severity and can be used to predict the future disability. 
Activated macrophages and synovial ﬁ broblasts produce MMPs that degrade 
extracellular matrix, and cytokines and proangiogenic factors that contribute to the 
inﬂ ammation and to the formation of vasculature. Endothelial cells in the synovium 
are activated and they express adhesion molecules, such as ICAM-1, that promote 
the recruitment of inﬂ ammatory cells into the joint. Th is process is enhanced by the 
release of chemokines by inﬂ ammatory cells in the joint.
2.2.2 Cytokines in RA
Th e term cytokine is applied to a rapidly growing group of small proteins or 
glycoproteins that serve as chemical messengers between cells. Cytokines are 
involved in critical processes as cell growth and diﬀ erentiation, tissue remodelling, 
and regulation of the immune response. In acute and chronic inﬂ ammation 
cytokines play a key role in regulating the nature, magnitude and duration of the 
inﬂ ammatory response. Most cytokines are expressed transiently after an inducing 
stimulus. One of the most potent signals for inducing the production of cytokines 
is other cytokines. Th us, cytokines create a network, in which they interact in 
synergistic, complementary, antagonistic or inhibitory manner. Th e dysregulation of 
this cytokine network is an important feature of the pathology of RA, and as such, 
cytokines represent an important therapeutic target for antirheumatic treatment. 
Th ere is considerable evidence that TNF-α and IL-1β are the key mediators 
that drive inﬂ ammation and tissue degradation in RA. As illustrated in Figure 2, 
Figure 2.  IL-1β and TNF-α are the key mediators that drive inﬂ ammation and 
tissue degradation in RA (modiﬁ ed from Dayer 2003).
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both cytokines inﬂ uence local and systemic disease manifestations in a synergistic 
manner. Also numerous other cytokines have been implicated in RA and an overview 
of them is presented in Table 2. In this review, the role of TNF-α, IL-1β and IL-1Ra 
is discussed in more detail.
Th e apprehension that TNF-α is one of the most important factors in the 
pathogenesis of RA was ﬁ rst realized approximately 15 years ago. In 1988, Di Giovine 
et al. detected that TNF-α levels are increased in synovial ﬂ uid and serum of RA 
Table 2.  Pro- and anti-inﬂ ammatory cytokines in rheumatoid arthritis 
(reviewed in Choy and Panayi 2001). 
IL=interleukine, TNF=tumor necrosis factor, TIMP=tissue inhibitor of metalloproteinases, 
MCP=monocyte chemoattractant protein, PG=prostaglandin, NO=nitric oxide
Cytokine Function Effect
IL-2 stimulates T-cell proliferation proinfl ammatory
IL-6
 
induction of immunoglobulin production in B cells
activation of T cells
proliferation of synovial fi broblasts
induction of acute phase response
proinfl ammatory 
down-regulation of TNF- and IL-1  
induction of synthesis of TIMP
anti-infl ammatory
 
IL-7
 
expression of adhesion molecules
stimulates immunoglobulin synthesis
proinfl ammatory
 
IL-8
 
induces neutrophil infi ltration and activation
stimulates angiogenesis
proinfl ammatory
 
IL-15
 
recruitment, migration and activation of T cells
inhibition of T cell apoptosis
induction of production of IL-8 and MCP-1
proinfl ammatory
 
IL-4
 
inhibition of T cell activation
inhibition of TNF-, IL-1, IL-6 and IL-8 production
increase in IL-1Ra production
anti-infl ammatory
 
IL-10 inhibition of the production TNF- and IL-1 
inhibition of the T cell proliferation
anti-infl ammatory
IL-18
 
production of TNF- and IL-1 
expression of adhesion molecules
proinfl ammatory
 
IL-11 decrease in TNF- and IL-1 anti-infl ammatory
IL-13
 
decrease in TNF- , IL-1, PgE2 and NO
increase in IL-1Ra
anti-infl ammatory
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patients. TNF-α expression was also shown to be increased in the inﬂ amed joints 
of animals with experimentally induced arthritis and in patients with RA (Firestein 
et al. 1990). Transgenic mice overexpressing TNF-α were found to spontaneously 
develop an erosive arthritis (Keﬀ er et al. 1991). Furthermore, several investigators 
noticed that administration of TNF-α exacerbated arthritis and inhibitors of TNF-
α reduced the severity of inﬂ ammation (Cooper et al. 1992, Piquet et al. 1992, 
Williams et al. 1992). Th ese ﬁ ndings led to years of intense research culminating in 
the introduction of anti-TNF-α therapies for RA in the beginning of 21st century.
TNF-α is a soluble 17 kD protein composed of three identical subunits. TNF-α is 
bound to cell membrane until cleaved by TNF-α converting enzyme (TACE) (Black 
et al. 1997). Biological responses to TNF-α are mediated via two structurally distinct 
receptors, type I (TNFRI) and type II (TNFRII). Both receptors are expressed on 
all cell types except erythrocytes. Both TNF-α receptors are subject to proteolytic 
cleavage and are shed from the cell surface in response to inﬂ ammatory signals. Th e 
shed receptor retains its ability to bind TNF-α, thus acting as a natural inhibitor of 
TNF-α activity. Both soluble inhibitors are readily detectable in rheumatoid synovial 
ﬂ uids, but in concentrations insuﬃ  cient to neutralize endogenous production of 
TNF-α (Cope et al. 1992, Steiner et al. 1995). Th e expression of TNF-α receptors is 
upregulated in an active RA tissue (Alsalameh et al. 1999) and TNF-α receptors are 
expressed by a variety of cell types in RA synovial tissue, indicating that abundant 
cells are potential targets for TNF-α (Deleuran et al. 1992).
While TNF-α is physiologically vital in activating the innate and acquired 
immune response against pathogens, it is obvious that inappropriate production 
of TNF-α leads to inﬂ ammation and tissue destruction. TNF-α is produced by 
numerous cell types including immune cells (B cells, T cells, basophils, eosinophils, 
monocytes, macrophages, dendritic cells, NK cells, neutrophils and mast cells), 
nonimmune cells (such as ﬁ broblasts, osteoclasts and smooth muscle cells) and 
generally tumour cells (Bazzoni and Beutler 1996, Pfeﬀ er 2003, Ghezzi and Cerami 
2004). Immunohistochemical studies of RA synovium have localized TNF-α 
predominantly in macrophages (Chu et al. 1991, Tetlow and Woolley 1995a). 
However, TNF-α has also been found to be expressed by synovial mast cells in RA 
tissues (Woolley and Tetlow 2000).
TNF-α alone is not especially arthritogenic, as antibodies against IL-1 receptor 
completely arrest the arthritis in TNF-α transgenic mice model of chronic arthritis, 
even if the TNF-α levels reside high (Probert et al. 1995, van den Berg 2002). Th e 
power of TNF-α is that it is the prime cytokine stimulating and co-ordinating 
the overall cytokine response. Th is provides a rationale for therapeutic targeting. 
Th e ﬁ nding by Brennan et al. (1989), that blocking TNF-α leads to a signiﬁ cant 
decrease in the production of IL-1β, was the cornerstone for the development of 
anti-TNF-α therapy for treatment of RA. Th e concept was further strengthened 
by the ﬁ ndings that blocking TNF-α reduces the expression of also multiple other 
proinﬂ ammatory cytokines in synovial tissue, such as granulocyte-monocyte colony 
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stimulating factor (GM-CSF) (Haworth et al. 1991), IL-6 and IL-8 (Butler et al. 
1995). Anti-TNF-α based therapies have proven highly eﬀ ective in the treatment of 
RA, furthermore conﬁ rming the role of TNF-α in the pathogenesis of RA (Elliott 
et al. 1993 and 1994, Feldmann and Maini 2001). Also the hypothesis, that TNF-α 
orchestrates the cytokine response, has been conﬁ rmed in vivo by the ﬁ ndings that 
levels of IL-6 (Charles et al. 1999), VEGF (Paleolog et al. 1998), IL-8 and other 
chemokines (Taylor et al. 2000) are decreased in response to anti-TNF-α treatment 
in patients with RA.
When the general interest on cytokines in the pathophysiology of RA greatly 
increased in late 80’s to early 90’s, also IL-1β emerged as a key contributor in the 
disease. Patients with active RA were shown to have elevated IL-1β concentrations 
in plasma (Fontana et al. 1982, Eastgate et al. 1988). Th e level of IL-1β in serum was 
found to generally correlate with the disease severity (Cannon et al. 1993). Injection 
of IL-1 into the knee joints of rabbits was shown to give rise to the degradation of 
cartilage (Pettipher et al. 1986). Furthermore, the administration of antibodies to 
IL-1 completely prevented the development of arthritis in TNF-transgenic mouse 
model (Probert et al. 1995). IL-1β is involved in several central pathological processes 
related to RA as it stimulates the expression of proinﬂ ammatory mediators, tissue-
damaging enzymes and antiapoptotic molecules in synovial ﬁ broblasts (Jeong et al. 
2004). IL-1β expression tends to be increased in end stage of RA, suggesting a major 
role of IL-1β in joint destruction (Smeets et al. 2003). Th e last line of evidence for 
the pivotal role of IL-1 in RA comes from studies showing that speciﬁ c blocking of 
IL-1β reduces the intensity and destructive nature of the disease (van den Berg et al. 
1994, Campion et al. 1996, Bresnihan et al. 1998, Bendele et al. 1999).
Th e interleukin-1 family consists of seven individual members. Of these, three 
members, IL-1α, IL-1β and IL-1Ra are thoroughly studied in the context of RA. 
IL-1β binds to two types of cell surface receptors. Only IL-1RI has a cytoplasmic 
tail and is capable of evoking intracellular signal (Sims et al. 1993). IL-1RII is a 
decoy receptor, as it binds IL-1 but do not deliver any intracellular signal (Colotta 
et al. 1993). Both IL-1 receptor types are found also in soluble form. Soluble forms 
compete with cell-surface receptors, thus decreasing the biological activity of IL-1. In 
addition, a naturally occurring antagonist, IL-1Ra, binds to IL-1RI without triggering 
a signal (Svenson et al. 1995). Th us, the biological activity of IL-1 is physiologically 
regulated by three diﬀ erent mechanisms. Similarly to TNF-α, IL-1β is produced by 
macrophages and monocytes, but also other cell types like endothelial cells, synovial 
lining cells, B cells and activated T cells (Koch et al. 1995). In immunohistochemical 
studies on rheumatoid synovial tissue, IL-1β has been shown to be expressed in cells 
neighbouring mast cells (Woolley and Tetlow 2000).
TNF-α and IL-1β have a signiﬁ cant overlap in their biological eﬀ ects and their 
synergism is marked concerning inﬂ ammation and tissue remodeling. In general, TNF-
α seems to be more important at the systemic level and in the inﬂ ammatory context, 
while IL-1β acts at the local level and is central in the development of erosions. It is 
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evident that TNF-α induces the production of IL-1β and vice versa (Nawroth et al. 
1986, Dinarello et al. 1986, Phillip and Epstein 1986, Probert et al. 1995). Practically 
all cells express receptors for TNF-α and therefore respond to it. IL-1β induces the 
production of proteolytic enzymes, such as MMPs, and activates osteoclasts, both 
eﬀ ects playing a key role in the development of cartilage and joint erosions. 
IL-1Ra is a naturally occurring antagonist of IL-1. It binds to IL-1R with high 
aﬃ  nity without evoking a signal thus inhibiting the binding of agonistic IL-1. Th e 
inhibitory function of IL-1Ra appears to be unique in cytokine biology. Neutrophils 
and mononuclear cells are the main sources of IL-1Ra (Malyak et al. 1993, Firestein 
et al. 1994), but also rheumatoid synovial ﬁ broblasts have been shown to produce 
IL-1Ra (Chomarat et al. 1995). Th e importance of IL-1Ra in counteracting the 
destructive eﬀ ects of IL-1β was shown in mice deﬁ cient in the IL-1Ra gene, which 
spontaneously developed arthritis and erosions of the articular bone (Horai et al. 
2000). 
Th e relative production of IL-1β to IL-1Ra is fundamental in the pathophysiology 
of RA. Th e concentrations of IL-1Ra are high in the synovial ﬂ uid of RA patients, 
but not high enough to bind all the excess IL-1β for suppression of inﬂ ammation 
(Chomarat et al. 1995). Less than 5% of IL-1 receptors need to be engaged by 
IL-1β in order to induce a biological response, and it is estimated that a 10- to 100-
fold excess of IL-1Ra is necessary to achieve a 50% inhibition of the IL-1 response 
(Arend et al. 1990). Th us, the reported elevation of IL-1Ra in rheumatoid synovial 
ﬂ uids appears insuﬃ  cient to abolish IL-1β-induced inﬂ ammatory responses.
2.2.3 MMPs in RA
Th e matrix metalloproteinases (MMPs) are a large group of enzymes responsible for 
matrix degradation and turnover in both physiology and pathology. Th ey contribute 
to joint destruction in RA by directly degrading the cartilage and bone and indirectly 
by promoting angiogenesis. Th e imbalance between MMP expression, activation, 
and inhibition is implicated in RA (Murphy et al. 2002, Mohammed et al. 2003, 
Firestein 2003, Tchetverikov et al. 2004). Aggrecanase and collagen are the major 
components of the joint cartilage that are subjects to proteolytic degradation by 
MMPs. MMP-1 (collagenase-1), MMP-13 (collagenase-3) and MMP-3 (stromelysin-
1) are presumed to play central roles in the cartilage destruction associated with 
rheumatoid arthritis and their expression has been shown to be markedly increased 
in the synovium of patients with active RA (Konttinen et al. 1999a). 
In rheumatoid synovium, synovial ﬁ broblasts and chondrocytes are the major sources 
of MMPs. TNF-α and especially IL-1β are known to induce MMP expression in 
SFB (Dayer et al. 1985, Kumkumian et al. 1989). Furthermore, these cytokines 
have been detected at the same areas as the increased MMP activity in the RA tissue 
(Konttinen et al. 1999b), signifying the role of this induction in RA.
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2.3 MAST CELLS IN RA 
Th e role of mast cells in inﬂ ammatory arthritis has been discussed since 1980 s´ 
(Wasserman 1984, Crisp 1984a, Mican and Metcalfe 1990). Th e observed mast 
cell hyperplasia in inﬂ amed synovium and the exceptionally broad panel of potent 
proinﬂ ammatory eﬀ ectors released by activated mast cells gave rise to the concept 
of mast cell being a forceful player in synovial inﬂ ammation. Furthermore, the 
comprehension that mast cells are activated by immune complexes and complement 
fragments strenghthened the hypothesis of their involvement in synovitis. A recent 
breakthrough, describing the mast cells as a key cell type in RA animal model (Lee 
et al. 2002), has again made the conversation lively around the subject (Woolley 
2003, Nigrovic and Lee 2005). To date, it has become evident that mast cells are 
involved in the pathogenesis of RA. Figure 3 sums up the dimensions discussed in 
this chapter.
2.3.1 Mast cell hyperplasia
An increased density of mast cells in RA synovium is a consistent ﬁ nding (Wyenne-
Roberts et al. 1978, Godfrey et al. 1984, Crisp et al. 1984b, Gotis-Graham 
and McNeil 1997). It has been estimated that mast cells normally constitute 
Figure 3. Mast cell in inﬂ ammatory arthritis. 
(Arthritis Res Th er. 2005;7:1-11, with permission of the copyright holder).
 TNF=tumor necrosis factor, IL=interleukin, MCP=monocyte chemoattractant protein, 
PMN=polymorphonuclear cells, IFN=interferon, bFGF=basic ﬁ broblast growth 
factor, PDGF=platelet-derived growth factor, SCF=stem cell factor, MMP=matrix 
metalloproteinase, RANK-L=receptor activator of NF-kappaB-ligand , M-
CSF=macrophage-colony stimulating factor, MIP=macrophage inﬂ ammatory protein. 
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approximately 3 % of all cells within synovium, and that this proportion is increased 
up to 5 % or more in RA synovium (Nigrovic and Lee 2005). Th e degree of mast 
cell hyperplasia in synovial tissues seems to be related to the degree of clinical 
synovitis, the extent of lymphocytic inﬁ ltration and the activity of RA (Malone et 
al. 1987, Gotis-Graham and McNeil 1997, Gotis-Graham et al. 1998). Increased 
SCF levels have been detected in synovial ﬂ uid of RA patients (Carsons et al. 2000), 
and increased inﬁ ltration and maturation of mast cell progenitors appear to be 
the main reasons for hyperplasia in synovium (Ceponis et al. 1998). Mast cells are 
present throughout the synovial sublining with accumulations in pannus near sites 
of erosions (Tetlow and Wooley 1995a and 1995b). Mast cells are also present in the 
synovial ﬂ uid of patients with RA. Synovial ﬂ uids from patients with RA have been 
shown to exhibit mast cell chemotactic activity, which might be one explanation 
for the observed mast cell hyperplasia (Olsson et al. 2001). As activation of mast 
cells induces expression of antiapoptotic molecules (Xiang et al. 2001, Möller et al. 
2003), an additional contributing factor might be reduced apoptosis of mast cells in 
RA synovium. Besides RA, synovial mastocytosis has been observed also in other 
arthritides, including juvenile RA, systemic lupus erythematosus, psoriatic arthritis, 
and osteoarthritis (Godfrey et al. 1984).
2.3.2 Mast cells and chronic infl ammation
Accompanying the increased number of mast cells, mast-cell-speciﬁ c mediators are 
elevated in the synovial ﬂ uid of RA patients indicating continuing mast cell activation 
(Malone et al. 1986, Buckley et al. 1997). Th e role of mast cells in inﬂ ammation 
is twofold. Th ey contribute directly to the production of inﬂ ammatory cytokines 
but probably even more important is their capacity to recruit and stimulate other 
eﬀ ector cells. 
Th e greatly expanded number of inﬂ ammatory cells is a prominent feature of 
RA synovium. Mast cells induce expression of adhesion molecules on endothelial 
cells (Walsh et al. 1991) and secrete an array of chemotactic mediators thus 
recruiting neutrophils and lymphocytes (Kharazmi et al. 1988, Strieter et al. 1989). 
Furthermore mast cell mediators increase vascular permeability thus facilitating the 
passage of inﬂ ammatory cells. 
Macrophages and T-cells are well-known for their contribution to synovitis 
related to RA (reviewed in Firestein 2003). Mast-cell-derived mediators, such as 
TNF-α, IL-6, GM-SCF and MCP-6 activate macrophages and T cells and thus 
upholding the chronic inﬂ ammation in the joint.
2.3.3 Mast cells and angiogenesis
Formation of new blood vessels is a characteristic feature of inﬂ amed synovium. 
Angiogenesis begins very early in the course of RA. Angiogenesis ensures development 
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and persistence of the pannus by increasing the supply of oxygen, nutrients, cytokines, 
and inﬂ ammatory cells to the synovial membrane. Clinical disease severity in RA 
patients is correlated with the intensity of angiogenesis, as evaluated by VEGF levels 
or other parameters (Clavel et al. 2003). In several studies, VEGF levels have been 
found to be higher in synovial ﬂ uid or blood from RA patients than from controls 
(Fava et al. 1994, Koch et al. 1994, Paleolog et al. 1998). Furthermore, VEGF 
levels were correlated with clinical and laboratory markers for disease activity and 
progression in patients with RA (reviewed in Clavel et al. 2003).
Fibroblasts and endothelial cells are the main sources of proangiogenetic 
cytokines, including PDGF, VEGF and bFGF. However, in synovium, mast cells 
reside closely associated with blood vessels and are found at sites of angiogenesis 
(Norrby 2002). Mast cells exert proangiogenic eﬀ ect as they produce several 
proangiogenic mediators, including VEGF, bFGF and IL-8 (Yamada et al. 1998, 
Qu et al. 1995, Norrby 2002). Furthermore, mast cell proteases, such as tryptase 
and MMPs, support the process by degrading connective tissue matrix to provide 
space for new capillaries. In addition to direct eﬀ ects, mast cells indirectly stimulate 
angiogenesis by secreting TNF-α and IL-1β, both of which greatly enhance the 
expression of VEGF by other cell types (reviewed in Norrby 2002).
2.3.4 Mast cells and fi brosis
Mast cells are known to be a source of ﬁ brogenic cytokines, including PDGF and 
bFGF (Qu et al. 1995, Artuc et al. 2002). In accordance with this mast cells have been 
shown to stimulate ﬁ broblast proliferation (Trautmann et al. 1998). Th e supportive 
eﬀ ect is bidirectional as SFB produce SCF, which is the main growth factor for 
mast cells, and thus stimulate mast cell chemotaxis and support mast cell survival 
in synovial tissue (Ceponis et al. 1998, Kiener et al. 2000). Interactions between 
primary pulmonary ﬁ broblasts and mast cells have been shown to result in increased 
mast cell activity (Hogaboam et al. 1998). Th is induction was shown to depend on 
transmembrane SCF and require cell-cell contact. Given that both the ﬁ brogenic 
cytokines and SCF are found to be elevated in RA, the bidirectional interaction 
between SFB and synovial mast cells is likely to contribute to the pathogenesis of 
RA. Similar two-way interactions have been detected also between macrophages 
and ﬁ broblasts (Scott et al. 1997, Wang et al. 1997).
2.3.5 Mast cells and tissue degradation
Th e destruction of cartilage and bone is characteristic for RA and it is the ultimate 
reason for the loss of joint function. Mast cells secrete proteinases, such as tryptase, 
chymase and others, which directly degrade cartilage. Secondly, mast cells also have 
the potential to stimulate the expression of degrading enzymes, mainly MMPs, in 
neighbouring cells, including ﬁ broblasts and chondrocytes. Simultaneously mast 
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cells also directly stimulate osteoclast diﬀ erentiation and activation, which are 
mainly responsible for bone erosions in RA (Kobayashi et al. 2000). Furthermore 
mast cells attribute to osteoclast activity by inducing the production of osteoclast 
stimulating cytokines, such as RANK-L, by synovial ﬁ broblasts (Gravallese et al. 
2000, Nigrovic and Lee 2005). 
In RA synovial tissue, mast cells are found at sites of cartilage erosions (Bromley 
et al. 1984) and mast cell activity has been associated with expression of MMPs 
in the tissue (Tetlow and Woolley 1995b). Mast cell activation has been shown to 
elevate MMP production in rheumatoid synovial tissue (Tetlow and Woolley 1995a, 
Tetlow et al. 1998). Mast cell tryptase and chymase activate in vitro the precursor 
forms of MMPs (Gruber et al. 1988a, Saarinen et al. 1994), further intensifying the 
eﬀ ect of mast cells on tissue degradation. All this suggest that mast cells participate 
to the degradative processes within RA.
2.3.6 Mast cells in animal models of RA
In vitro mast cells exhibit several characteristics, which propose their involvement in 
arthritis in vivo. Th e role of mast cells in experimental arthritis has been investigated 
for over 30 years now (Gryfe et al. 1971, van den Broek et al. 1988). Quite recently, 
Lee et al. (2002) made a hallmark observation that mast cells are crucial for the 
development of erosive arthritis in response to autoantibodies in mice. Administration 
of serum from arthritic K/BχN mice induces arthritis in recipient mice (Korganow 
et al. 1999). However, the arthritogenic serum failed to induce arthritis in Sl/Sld or 
W/Wv murine strains, which lack functional mast cells. Importantly, engraftment 
of mast cells restored the susceptibility of W/Wv mice to arthritis. Lee et al. (2002) 
observed mast cell degranulation speciﬁ cally in synovial tissue and it was related to 
synovial hyperplasia, cartilage and bone destruction and inﬂ ammatory ﬁ ltrates. Th e 
signs of arthritis were absent in mast cell deﬁ cient mice. 
2.3.7 Clinical evidence for the involvement of mast cells in RA
Clinical evidence for the involvement of mast cells in RA is limited. Th e research on 
this ﬁ eld has been hampered by the lack of eﬃ  cient and selective inhibitors of mast 
cell functions. Administration of corticosteroids results in clinical improvement and 
can be accompanied by a decrease in mast cell numbers (Malone et al. 1987), but 
the eﬀ ect of corticosteroids is naturally not mast cell speciﬁ c. Recently, a drug that 
inhibits a key growth factor receptor expressed on mast cells, namely imatinib, has 
become available. Th e compound has been shown to inhibit growth of malignant 
mast cell line cells (Heindrich et al. 2000). Eklund and Joensuu (2003) have published 
a pilot clinical study with three RA patients, all of whom proﬁ ted from imatinib 
during the 12 week period. In addition, Miyachi et al. (2003) observed a beneﬁ t in 
one RA patient treated with imatinib because of CML. A single patient with RA 
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at Helsinki University Central Hospital has been treated with imatinib for nearly 3 
years and the activity of RA was very low during the entire treatment period. After 
3 months of treatment with imatinib, synovial tissue of this patient contained only 
a few mast cells as judged by immunohistochemical analysis (unpublished data). 
Th us, eliminating synovial mast cells could oﬀ er beneﬁ t in RA indicating that these 
cells are involved in the disease process. However, whether the possible depletion of 
synovial mast cells is related to the antirheumatic eﬀ ect of imatinib is currently not 
known.
2.4 SYNOVIAL FIBROBLASTS IN RA
Th e synovium is normally a relatively acellular structure with a delicate lining. Th e 
lining cells consist of macrophage-like (type A) synoviocytes and ﬁ broblast-like (type 
B) synoviocytes. In RA, a marked hyperplasia of synovial ﬁ broblasts (SFB) leads to 
thickening of the synovial membrane and to formation of pannus (Konttinen et al. 
2000, Ritchlin 2000). Th e histological appearance of SFB in RA is characterized 
by expansion of endoplasmic reticulum and increase in the number of cytoplasmic 
granules, suggesting an increased synthetic activity (Smith et al. 1997, Pap et al. 
2000). In the natural course of RA, the normally subtle synovial membrane is 
transformed into a proliferating invasive cell mass, consisting mostly of ﬁ broblasts 
and macrophages, but also of mast cells, polymorphonuclear leukocytes, dendritic 
cells and plasma cells (Bromley and Woolley 1984). 
Th e expanding pannus tissue erodes the surrounding articular tissue and bone. 
Current evidence shows that synovial cells act as the main eﬀ ector cells in the joint 
destruction of RA through invading and degrading the cartilage tissue (Konttinen et 
al. 2000, Pap et al. 2000, Ritchlin 2000, Tolboom et al. 2002). Th is process destroys 
local articular structures, which is devastating to the joint function. Moreover, 
synovial cells are likely to have a fundamental role in upholding synovitis as they 
release chemokines, that recruit inﬂ ammatory cells to the joint, and cytokines that 
both elicit inﬂ ammation and trigger angiogenesis (Smith et al. 1997).
Inﬂ ammatory cells are present in rheumatoid synovium and they induce 
proliferation of SFB by releasing PDGF and other stimulating growth factors 
(Konttinen et al. 2000). Stimulated mast cells and macrophages produce large 
amounts of proinﬂ ammatory cytokines, in this case mainly TNF-α and IL-
1β, which are potent inducers of proliferation and activation of SFB. IL-1β has 
been shown to provoke a series of responses in SFB including enhancement of 
inﬂ ammatory cytokines, imbalanced production of MMPs and tissue inhibitors of 
metalloproteinases (TIMPs), and dysregulation of apoptosis (Jeong et al. 2004), all 
strongly implicated in the pathology of RA. In the vicious circle of inﬂ ammatory 
arthritis, SFB further stimulate the recruitment inﬂ ammatory cells to synovium 
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(Smith et al. 1997, Kiener et al. 2000), thus triggering their own stimulatory 
signals.
Th e invasive growth of pannus is enabled by SFB capability to express 
degradative enzymes, MMPs in particular, that digest the extracellular matrix in 
the joint (Tolboom et al. 2002). SFB also stimulate the diﬀ erentiation and activation 
of osteoclasts, resulting in bone erosion (Gravallese et al. 2000). Additionally, in 
response to stimulation, synovial cells produce proinﬂ ammatory cytokines that 
facilitate the persistence of chronic inﬂ ammation in the aﬀ ected joint.
In the search for new eﬀ ective treatments for RA, one important approach could be the 
inhibition of the overgrowth and the synthetic activity of SFB. Th erefore understanding 
of the factors that attribute to stimulation of SFB is essential. In the chronically inﬂ amed 
synovium, RA synovial ﬁ broblasts grow aggressively under the continuous stimulatory 
signals. Th ese cells have typically defective contact inhibition, which leads to tumour-like 
growth. Mutations in key growth regulating genes, like tumour suppression gene p53, 
have been suggested to be involved in RA synovial ﬁ broblast proliferation (Pope 2002). 
Several anti-apoptotic molecules are expressed in SFB, and reduced rate of apoptosis 
is likely to be one reason for SFB hyperplasia in RA. Inhibition of proliferation and 
induction of apoptosis in SFB are considered as attractive therapeutic approaches in the 
treatment of RA (Pope 2002, Baier et al. 2003).
2.5 CHEMICALLY MODIFIED TETRACYCLINES
Tetracyclines are a group of antibiotic agents that have been proposed to hold 
therapeutical eﬀ ects with subantimicrobial doses in treatment of RA and osteoarthritis 
(Ryan et al. 1996, Golub et al. 1998, Stone et al. 2003). However, in the long-term 
use, the antimicrobial properties of tetracyclines may evoke undesirable side eﬀ ects, 
such as gastrointestinal disturbance and antibiotic resistance. Chemically modiﬁ ed 
tetracyclines (CMTs) are tetracycline derivates lacking the antibiotic activity of 
tetracyclines but possessing their anti-inﬂ ammatory properties.
Golub et al. (1987) found that removal of the dimethylamino group from the 
carbon-4 position of the A-ring of the 4-ringed tetracycline structure eliminates 
the antimicrobial activity while retaining the anticollagenolytic activity. Th is 
modiﬁ cation created CMT-1. Further modiﬁ cations of CMT-1 have generated 
CMTs with more potent anti-collagenolytic activity, oral bioavailability and long 
serum half-life. Elimination of the methyl and the hydroxyl groups of CMT-1 
resulted in CMT-3. To date more than 30 diﬀ erent CMTs have been synthesized 
and characterized. Th e chemical structures of CMT-1, CMT-3, CMT-8, CMT-308 
and doxycycline are presented in Figure 4.
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2.5.1 Effects of CMTs
Recent research has shown that the CMTs are pluripotent drugs that aﬀ ect many 
cellular functions including proliferation, migration, and matrix remodeling. Th e 
most prominent eﬀ ect of CMTs is the inhibition of matrix metalloproteinases 
(MMPs). Th e proposed mechanism of action of CMTs results from their ability to 
bind metal ions, particularly Zn2+ and Ca2+, which are required by many enzymes 
to maintain their proper conformation and hydrolytic activity. CMT-3 inhibits 
eﬀ ectively especially MMP-2 and MMP-9 (Acharya et al. 2004), but has also shown 
potency against MMP-1, MMP-3, MMP-8 and MMP-13 (Hanemaaijer et al. 1998, 
Golub et al. 1998).
Another interesting property of CMTs is their capacity to induce apoptosis. 
CMTs have been reported to prevent proliferation and to induce apoptosis in several 
malignant cell lines (D’Agostino et al. 2003, Lokeshwar et al. 2002, Tolomeo et 
al. 2001, Meng et al. 2000, Seftor et al. 1998). But CMT-3 has also been reported 
to induce apoptosis in some nonmalignant cultured cells, i.e. human osteoclasts 
(Holmes et al. 2004) and rat smooth muscle cells (Islam et al. 2003). Th e proapoptotic 
eﬀ ect of CMTs possibly contributes to the observed anticancer eﬃ  cacy of CMTs.
Figure 4.  Chemical structures of 
CMT-1 (4-dedimethylamino 
tetracycline), CMT-3 
(6-demethyl, 6-deoxy, 4 de-
dimethylamino tetracycline), 
CMT-8 (6-α deoxy, 5-hydroxy 4 
de-dimethylamino tetracycline), 
CMT-308 (9-aminoCMT-3) and 
doxycycline.
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In addition, CMTs have been described to exert several anti-inﬂ ammatory 
characteristics, including inhibition of phospholipase A2, inhibition of NO synthesis 
(D'Agostino et al. 2003, Tolomeo et al. 2001), inhibition of COX-2-mediated PGE2 
production (Patel et al. 1999) and inhibition of IL-6 formation (Kirkwood et al. 
2003). Th e clinical signiﬁ cance of these ﬁ ndings is still to uncover.
2.5.2 CMT-3
CMT-3 (Metastat®, CollaGenex Pharmaceuticals, USA) is the ﬁ rst non-antimicrobial, 
chemically modiﬁ ed tetracycline assessed in clinical trials for anticancer eﬀ ects in 
humans. On the basis of the promising preclinical studies (Cianfrocca et al. 2002, 
Rudek et al. 2001), CMT-3 is currently undergoing phase II trials for the potential 
treatment of metastatic cancer and HIV-related Kaposi's sarcoma. Th e results from 
this phase II clinical study indicate that CMT-3 potentially oﬀ ers signiﬁ cant beneﬁ ts 
for Kaposi's sarcoma patients (Press release 30.4.2004, CollaGenex Pharmaceuticals, 
USA). However, CMT-3 has shown eﬃ  cacy also in other cancer diseases (Rudek et 
al. 2001, Syed et al. 2003).
Th e pharmacokinetics of CMT-3 in humans has been clariﬁ ed (Rudek et al. 
2001 and 2003, Cianfrocca et al. 2002, Syed et al. 2003). Th e main side eﬀ ect of 
CMT-3, observed in 69 % of patients, is cutaneous photosensitivity. Th e frequency 
and severity of photosensitivity is dose-related and this side eﬀ ect is the dose-limiting 
factor (Rudek et al. 2001, Syed et al. 2003). Nevertheless, biologically relevant 
concentrations are readily maintained at doses, which do not give rise to severe 
toxicity (Syed et al. 2003). Th e main mechanism regarding the antitumour activity 
of CMT-3 is believed to be the inhibitory eﬀ ect on MMPs (Acharya et al. 2004). 
MMPs are implicated in tumour invasion and metastasis. In advantage, compared 
to other MMP inhibitors, CMT-3 also possesses antiproliferative and proapoptotic 
activity. Furthermore, CMT-3 has been shown in vitro to inhibit angiogenesis, an 
event that is critical for the growth of tumour (Fife et al. 2000).
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2.6 IMATINIB MESYLATE
Imatinib mesylate (imatinib, Glivec® or Gleevec®, Novartis, Switzerland) represents 
a new generation of molecularly targeted therapies designed to interfere speciﬁ c 
signal transduction pathways. Imatinib was formerly referred as STI571, and even 
in earlier studies known as CGP 57148B. Th e chemical structure of imatinib is 
presented in Figure 5.
2.6.1 Pharmacodynamic profi le 
Imatinib is a tyrosine kinase inhibitor with relatively selective activity against the 
bcr-abl tyrosine kinase, the abl-related gene ARG, platelet-derived growth factor 
receptor (PDGFR) and c-kit receptor (Druker et al. 1996, Buchdunger et al. 
2000, Heinrich et al. 2000). Recently, imatinib has been shown to inhibit also 
the macrophage colony-stimulating factor (M-CSF) receptor, c-fms (Dewar et al. 
2005).
Protein kinases are enzymes that transfer phosphate from adenosine triphosphate 
to speciﬁ c amino acids on substrate protein. Th e phosphorylation of these proteins 
leads to the activation of signal-transduction pathways, which have a critical role in 
a variety of biological processes, including cell growth, diﬀ erentiation and death. 
Protein kinases are composed of two subfamilies, the protein serine-threonine kinases 
and the protein tyrosine kinases (reviewed in Robinson et al. 2000). Th e deregulation 
of protein kinase activity plays a central role in the pathogenesis of human cancer and 
inhibition of protein kinases by selective pharmacological inhibitors is considered as an 
attractive therapeutic goal in treatment of cancers (Hanahan and Weinberg 2000).
Imatinib targets PDGFR (Buchdunger et al. 2000). Active PDGF molecules 
are dimeric isoforms that bind to two structurally similar tyrosine kinase receptors, 
PDGFR-alpha and PDGFR-beta. Because the PDGF isoforms are dimeric molecules, 
Figure 5. Chemical structure of imatinib mesylate. 
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their binding to the PDGFR causes dimerization, leading to autophosphorylation 
and activation of the kinase activity of the receptor (Figure 6). Th e c-kit receptor 
that bind SCF, is structurally similar to PDGFR Imatinib blocks the PDGF and 
c-kit signalling pathway by inhibiting the receptor autophosphorylation (Savage 
and Antman 2002). Imatinib has been shown to inhibit the kinase activity of the 
members of type III receptor tyrosine kinase family, except ﬂ t 3 tyrosine kinase 
(Buchdunger et al. 2000, Dewar et al. 2005).
2.6.2 Clinical indications
Imatinib was approved by the Food and Drug Administration (USA) and European 
Medicines Agency (EU) in 2001 for the treatment of chronic myeloid leukemia 
(CML) and in 2002 for the treatment of gastrointestinal stromal tumors (GIST).
Th e Bcr-Abl tyrosine kinase is the molecular abnormality behind CML, which is a 
myeloproliferative disorder. Th e Bcr-Abl protein is a constitutively activated tyrosine 
kinase (Sawyers 1999, Faderl et al. 1999). Imatinib inhibits this activity and it has 
revolutionized the drug therapy of CML (Druker et al. 2001). Th e exceptional level 
of eﬃ  cacy of imatinib is a result of precise targeting of the underlying cause of CML. 
Although a resistance to imatinib mesylate in CML patients have been observed, 
imatinib is at the moment a superior treatment for patients suﬀ ering from CML.
Mutated c-kit and PDGFR alpha tyrosine kinases are the principal targets for 
imatinib mesylate in the treatment of gastrointestinal stromal tumors. Most GISTs 
respond to imatinib mesylate, and it is the ﬁ rst treatment available for these patients. 
Imatinib is now considered as the standard systemic therapy for advanced GIST 
(Heinrich et al. 2003, Joensuu and Kindblom 2004).
Figure 6.  Imatinib mesylate inhibits the autophosphorylation of tyrosine kinase 
receptors for stem cell factor and platelet-derived growth factor. 
(N Engl J Med 2002;346:685, with permission of the copyright holder).
 ATP=adenosine triphosphate, ADP=adenosine diphosphate, P=phoshphate 
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2.6.3 Experimental fi ndings
In addition to indications approved by the authorities, imatinib has shown 
therapeutical potency in several disorders. Th e unique mechanism of action of 
imatinib has stimulated intensive research on numerous ﬁ elds of medicine.
Imatinib has shown to be eﬀ ective against mast cell malignancies driven by 
mutated c-kit. Pardanani et al. (2003) reported the eﬃ  cacy of imatinib in patients 
diagnosed with systemic mastocytosis. Half of these patients responded to imatinib 
therapy and 20 % of patients showed complete clinical and histological remission. 
In the perspective, that there is no current cure for mastocytosis, these results 
are noteworthy, and imatinib is considered useful in the treatment of systemic 
mastocytosis (Valent et al. 2005). However, relative resistance against imatinib exist, 
and it is associated with certain c-kit mutations (Valent et al. 2005).
2.7 TREATMENT OF RA
As the cause of RA is still elusive, no cure for the disease has been discovered. 
However, the treatment of RA has improved dramatically during the last 10 
years. Th e disease-modifying antirheumatic drugs (DMARDs) improve signs and 
symptoms of the disease as well as slow down the disease progression. Early and 
aggressive intervention with DMARDs is recommended as soon as the diagnosis 
is conﬁ rmed. Th e introduction of biological therapies targeted against TNF-α and 
IL-1β, in late 1990’s has begun a new era in the treatment of RA. In this review 
three antirheumatic treatments, methotrexate, TNF-α inhibitors and IL-1 receptor 
antagonist, are discussed in more detail. Th e latter two groups are also known as 
biological response modiﬁ ers (BRMs).
2.7.1 Disease-modifying antirheumatic drugs
DMARDs are drugs that besides reducing inﬂ ammation also slow the natural 
progress of the disease. Th ere is strong evidence that destruction occurs already in 
the early course of RA (Pincus et al. 1995) and to date there is general agreement 
that DMARDs should be introduced as early as possible and with adequate force, 
to suppress disease activity and thus possibly avoiding further joint damage and 
disability (Emery and Salmon 1995, Lard et al. 2002, Möttönen et al. 2002, O'Dell 
2002, Maillefert et al. 2003). Th e advantages of early and aggressive treatment of 
RA with DMARDs have been conclusively shown in Finnish patients in a 5 year 
follow-up study (Puolakka et al. 2004 and 2005, Korpela et al. 2005).
Th e eﬀ ect of DMARDs is seen in1-3 months after the onset of the medication. 
When monotherapy fails to achieve or sustain clinical remission, DMARDs are 
typically used as combinations (O'Dell et al. 1996, Möttönen et al. 1999, Pincus 
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1999, Zerkak and Dougados 2004). Safety proﬁ les of most DMARDs combinations 
are generally good (Zerkak and Dougados 2004). DMARDs currently in clinical 
use in Finland are listed in Table 3.
Methotrexate is considered as the ﬁ rst-in-line medication for RA and it is the 
most commonly used DMARD worldwide (Weinblatt 1995, Rau and Herborn 
2004). In most of the cases, it also creates the optimal basis for combination therapy 
(Pincus et al. 2003). In clinical research, methotrexate has been accepted as the "gold 
standard treatment" and the new therapies are evaluated against it. As typical for 
most of DMARDs, the precise mechanism of antirheumatic eﬀ ect of methotrexate 
is not completely understood. Th e classical mechanism of action of methotrexate 
is the inhibition of dihydrofolate reductase and other folate dependent enzymes 
leading to interference with the synthesis of pyrimidine and purines. Recently the 
ability of methotrexate to increase adenosine levels has been considered important to 
its antirheumatic eﬃ  cacy (Rau and Herborn 2004). Low-dose methotrexate in RA 
treatment seems to exert anti-inﬂ ammatory eﬀ ects by acting at diﬀ erent levels of the 
pathophysiological cascade (Cutolo and Straub 2001).
Sulphasalazine Penicillamine
Methotrexate Azathioprine
Hydroxychloroquine Podophyllotoxin
Chloroquine Cyclophosphamide
Cyclosporine Infl iximab
Aurothiomalate Etanercept
Auranofi n Adalimumab
Chlorambucil Anakinra
Table 3. Disease-modifying antirheumatic drugs currently used in Finland.
2.7.2 Biological response modifi ers
To date, four biological treatments have been approved as therapies for RA. 
Inﬂ iximab is a chimeric (75 % human, 25 % mouse) IgG1 monoclonal antibody that 
neutralizes TNF-α. Adalimumab is a fully human monoclonal antibody to TNF-
α. Etanercept is a soluble TNF-receptor fusion protein that binds to circulating 
TNF-α blocking the interaction with the cell-surface receptor. Etanercept can also 
bind to cell surface bound TNF-α. Treatment with agents that block the function 
of TNF-α has proved to be a highly eﬀ ective approach in RA (Elliot et al. 1994 
and 1995, Feldmann and Maini 2001). In addition to RA, these treatments have 
been eﬀ ective in Crohn´ s disease (inﬂ iximab), spondyloarthropaties, psoriasis, and 
graft-versus-host reactions (Reimold 2003).
Many of the pathophysiological processes involved in RA have been shown to 
be prevented by the use of TNF-α inhibitors. TNF-α blockers provide relief against 
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pain and joint swelling in most RA patients (van den Berg 2001). Th e immediate 
immunological mechanisms resulting from blocking of TNF-α appear to be crucial 
since clinical improvement is seen within days after the onset of treatment. However, 
anti-TNF-α therapy is not eﬀ ective in all RA patients, indicating that multiple 
pathophysiological pathways exist.
Preventing erosions is central in antirheumatic therapy. Th e main mechanism for 
the erosive eﬀ ect of TNF-α is assumed to be the upregulation of IL-1β production 
(van den Berg 2002). TNF-α has been also proposed to stimulate directly 
proliferation of synovial ﬁ broblasts and diﬀ erentiation of osteoclast (Kobayashi et al. 
2000), which both are central in the development of bone erosions. Th e inhibition 
of these events could explain the antierosive eﬀ ect of TNF-α inhibitors seen in RA 
patients (Bresnihan 2002a).
Another approach is to interfere the biological activity of IL-1β. Anakinra is a 
recombinant human IL-1 receptor antagonist. Anakinra binds to IL-1 receptors, 
thereby blocking the binding and biological eﬀ ects of IL-1α and IL-1β (Arend et al. 
1990). Anakinra has been shown to produce clinically signiﬁ cant improvements in 
signs and symptoms of RA and in the functional status of RA patients (Bresnihan 
2002b). Th e therapeutic eﬀ ects occur early and are sustained throughout treatment 
over 76 weeks. As IL-1β is the key cytokine in stimulating degradative processes 
associated with RA, anakinra has expectedly slowed the rate of joint erosions 
signiﬁ cantly in comparison to placebo (Bresnihan 2002b). Th e long-term eﬀ ects 
of IL-1 blockage are still to uncover. In general, when comparing the eﬃ  cacy of 
diﬀ erent biological, the ACR responses observed with anakinra are smaller than 
those observed with TNF-α blockers.
2.7.3 Future aspects of the treatment of RA
To date, no antirheumatic treatment has fully prevented the progression of joint 
damage in all patients with RA. Hence, there is a clinical need for new drug candidates. 
Several promising molecules are in the last phases of the drug development process 
and some new treatments for RA are expected in the near future.
Th e importance of CD4+ T cells in autoimmune diseases, such as RA, is 
clear. Abatacept (CTLA4-Ig) is a novel fusion protein designed to modulate T cell 
activation through blocking the classic T cell co-stimulatory signal (Ruderman and 
Pope 2005). Two completed phase III studies have proved abatacept to be eﬀ ective 
in controlling the clinical signs and symptoms of RA (Mariette 2004, Ruderman 
and Pope 2005). Importantly, abatacept showed eﬃ  cacy in patient with inadequate 
response to methotrexate or anti-TNF-α therapy.
As RA has an autoimmune background, also B cells play a role in the pathogenesis 
by producing autoantibodies, presenting antigens, and secreting cytokines. 
Rituximab is a chimeric monoclonal antibody for CD20 and targets mature B-cells. 
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It was originally designed for treatment of B cell leukemias. Rituximab has shown 
eﬃ  cacy in phase II trials for treatment of RA (Edwards et al. 2004). 
Interleukines are considered as potential targets in chronic destructive 
arthritis. IL-6 levels are elevated in serum and joint ﬂ uid from patients with RA, 
and a correlation has been found between serum IL-6 levels and the severity of 
radiographic destruction (Dasgupta et al. 1992). A humanized anti-IL-6R antibody 
called tocilizumab (or MRA) has recently been found eﬀ ective in large phase II 
randomized placebo-controlled trials (Nishimoto et al. 2004). Blockade of IL-15 
has also been tested with promising results in RA (McInnes and Gracie 2004).
New potential drug targets emerge as the basic research on the pathogenesis of 
RA advances. However, one can not predict which of the cytokines or cell types 
contributing to the chronic inﬂ ammation would be the best targets to interfere. 
Several animal models of RA are available, and the obtained results from these 
investigations may suggest novel targets. However, several treatments which have 
shown promising results in animal models, have later on failed in clinical trials 
(Keystone 2002), emphasizing the importance of preclinical research on human 
tissues. As the understanding of the multidimensional network of cytokines and 
cells participating in the development of chronic and erosive joint inﬂ ammation in 
RA evolves, the discovery of a cure for this detrimental disease may become closer. 
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3.
AIMS OF THE STUDY
Th e purpose of the present study  was to investigate the role of mast cells in synovial 
inﬂ ammation and the ability of novel anti-inﬂ ammatory compounds to inhibit 
mast cell and synovial ﬁ broblast functions. Th e eﬀ ects of chemically modiﬁ ed 
tetracyclines and imatinib mesylate were studied in the present work.
Th is study was designed to test the following hypotheses:
1. Th e activation of synovial mast cells results in production of cytokines in 
rheumatoid synovial tissue (IV).
2. Chemically modiﬁ ed tetracycline-3 inhibits the activation of mast cells and 
ensuing secretion of mediators from mast cells (I).
3. Chemically modiﬁ ed tetracycline-3 inhibits the activity of protein kinase C (I).
4. Chemically modiﬁ ed tetracyclines induce apoptosis of mast cells (II).
5. Inhibition of c-kit signalling by imatinib mesylate induces apoptosis in mast 
cells (III).
6. Th e inhibition of PDGF receptor by imatinib mesylate inhibits the proliferation 
of rheumatoid synovial ﬁ broblasts (V).
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4.
MATERIALS AND METHODS
Th is chapter covers the materials and methods used in this thesis. A more detailed 
description of materials and methods is given in the respective original publications I-V.
4.1 Cell cultures
4.1.1 Human mast cell line
Th e human leukemic mast cell line (HMC-1) has been established from the 
peripheral blood of a patient with mast cell leukemia (Butterﬁ eld et al. 1988). 
HMC-1 cells were cultured in supplemented Iscove s´ medium. HMC-1 cells were 
used in cytokine release (I), proliferation (II, III), apoptosis (II, III) and caspase 
activity (II, III) studies.
4.1.2 Rat peritoneal mast cells 
Rat peritoneal mast cells (RPMC) were isolated from adult male Wistar rats (Test 
animal facilities, University of Helsinki, Finland). To collect the mucosal mast cells, 
thoracic and peritoneal cavities were lavaged with buﬀ er. Th e buﬀ er was centrifuged 
and cells were suspended into supplemented RPMI 1640 medium. Th e cells were 
incubated in a Petri dish for 1 h at +37 °C and non-adherent cells were collected 
and resuspended into fresh media. Th e purity of mast cells recovered was > 90 % as 
assessed by toluidine blue staining, which selectively stains mast cells. RPMC were 
used in histamine release (I, III) studies.
4.1.3 Mouse bone marrow derived mast cells
Mouse bone marrow derived mast cells (mBMMC) were isolated from 7-8 weeks 
old female BALB/c mice (Test animal facilities, University of Helsinki, Finland). 
Cells were harvested from bone marrow of femurs and tibias by repeated ﬂ ushings 
with RPMI. Th e cells were cultured in IL-3 containing WEHI:RPMI medium. 
Non-adherent cells were transferred to fresh medium twice a week for 3-4 weeks 
to remove adherent macrophages and ﬁ broblasts. Th e purity of mast cells derived 
as described has been reported to be relatively high (Eklund et al. 1994). mBMMC 
were used in proliferation (II, III) and apoptosis (II, III) studies.
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mBMMC were cultured in IL-3 containing WEHI:RPMI (50:50) media or 
in SCF containing KL:RPMI (1:5) media. Cultured murine myelomonocytic 
leukemia cell line, WEHI-3 cells (line TIB-68, ATCC; Rockville, MD) produce 
IL-3 and release it in the media (Lee et al. 1982). WEHI-3 cells were cultured in 
supplemented RPMI media for 5-7 days. Th en the ﬁ ltered media was suspended with 
an equal amount of fresh supplemented RPMI. Recombinant c-kit ligand (rKL) was 
produced in Cos cells by transiently transfecting the cells by electrocorporation with 
artiﬁ cially truncated KL cDNA (Flanagan et al. 1991). rKL containing Cos cell 
supernatant was used at dilution of 1:5 with supplemented RPMI corresponding 
approximately 150 ng/ml of rKL (Eklund et al. 1994). Before suspending cells 
cultured in IL-3 media, into rKL containing media the cells were washed three 
times with PBS to remove remaining IL-3.
4.1.4 Human mast cells obtained by culturing CD34+ stem cells
Human mast cells (HuMCs) were derived by culturing mononuclear CD34+ stem 
cells from cord blood, as described previously (Saito et al. 1995). Th e CD34+ cells 
were cultured in Iscove's Modiﬁ ed Dulbecco's Medium supplemented with 10 % 
FCS. First (weeks 1–3) the cells were cultured in the presence of human recombinant 
SCF, IL-6 and IL-10. During the following 5 weeks (weeks 4–8), the cells were 
cultured in the presence of SCF, and thereafter in the presence of SCF and IL-4. For 
the ﬁ rst 10 weeks, the cells were cultured in a low-oxygen atmosphere (5% O2–95 
% N2) and thereafter in a normal cell culture atmosphere (5 % CO2, ca. 20% 
O2). Th e maturity of cultured HuMCs was assessed by visualising the expression of 
tryptase and chymase and by determining histamine release. HuMCs were used in 
histamine release (I) and apoptosis (II and III) studies.
4.1.5 Human synovial fi broblasts
Human synovial ﬁ broblasts (SFB) were isolated from synovial tissue obtained from 
knee arthroplasties of patients with diagnosed RA. All patients met the American 
College of Rheumatology classiﬁ cation criteria for RA (Arnett et al. 1987). Th e study 
was approved by the ethical committee of surgery of the Helsinki University Central 
Hospital. Synovial cells were dissociated by collagenase treatment and cultured in 
supplemented Dulbecco´ s modiﬁ ed Eagles medium (DMEM). Before growing 
conﬂ uent cells were trypsinized and divided onto new cell culture plates. During 
the culture, macrophage-like synovial cells gradually disappear and ﬁ broblast-
like synovial cells proliferate. Th e phenotype of cultured cells was verifyied with 
immunohistochemical staining for ﬁ broblast speciﬁ c Th y-1 (see 4.9.2). Th e purity 
of SFB culture was approximately 90 %. Experiments were performed with synovial 
cells from 3 to 6 passages. SFB were used in proliferation (V) studies. 
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4.2 Synovial tissue explant cultures
Synovial tissue was obtained from knee arthroplasties of patients fulﬁ lling the 
revised criteria of the American College of Rheumatology (Arnett et al. 1987). Th e 
study was approved by the ethical committee of surgery of the Helsinki University 
Central Hospital. Tissue explants were cultured in Dulbecco´ s modiﬁ ed Eagle s´ 
medium. Cultures of synovial tissue explants were used to study mast cell apoptosis 
(III), histamine release and cytokine production (III and IV), and TNF-α (III) and 
IL-1β immunohistochemistry (IV). 
4.3 Activation of mast cells
4.3.1 Human mast cell line cells
HMC-1 cells were activated with a combination of PMA (50 ng/ml) and calcium 
ionophore A23187 (0.5 µM). Th is activation has been shown to produce an 
optimal cytokine release from HMC-1 cells (Lippert et al. 1996). Th e studied drug 
compounds were added 1 h prior to activation. Because activation reduces HMC-1 
viability to some extent during the 24 h incubation, the cells were stained with 
trypan blue and cell numbers were counted after incubation.
4.3.2 Rat peritoneal mast cells
RPMC cells were activated with compound 48/80 (5 µg/ml), which induces 
histamine release from RPMC (Bloom and Haegermark 1965). Th e studied drug 
compounds were added 1 h prior to activation. 20 min after activation cells and 
supernatants were separated by centrifugation and frozen for later analysis.
4.3.3 Human mast cells obtained by culturing CD34+ stem cells
HuMCs were ﬁ rst incubated with human IgE to coat the FcεRI and the studied 
drug compounds were added 1 h before the activation. Th ereafter HuMCs were 
activated by adding polyclonal anti-human anti-IgE. Culture media was collected 1 
h later for histamine analysis.
4.3.4 Human synovial tissue mast cells
Human synovial tissue mast cells were activated with rabbit IgG antibodies against 
human IgE (150 µg/ml). A nonspeciﬁ c rabbit IgG (150 µg/ml) was used as a control. 
A sample for histamine assay was taken after incubation for one hour and analysed 
for histamine content. Th e explants were incubated for 20-24 h, and then embedded 
in the O.C.T. compound-containing mould and frozen in liquid nitrogen. Culture 
media was collected and both explants and media were stored at -80 °C.
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4.4 Drug compounds
Chemically modiﬁ ed tetracycline -1 (4-dedimethylamino tetracycline), CMT-3 (6-
demethyl 6-deoxy 4 de-dimethylamino tetracycline), CMT-8 (6-α deoxy 5-hydroxy 
4 de-dimethylamino tetracycline), CMT-308 (9-aminoCMT-3) were kindly 
provided by CollaGenex Pharmaceuticals (Newtown, PA, USA). Doxycycline was 
purhaced from Sigma (St.Louis, MO, USA). Imatinib mesylate was a kind gift from 
Novartis (Basel, Switzerland).
4.5 Measurements of mediators
4.5.1 ELISA
To determine histamine release, RPMC (I) or HuMC (I) or tissue explants (III, IV) 
were treated with the studied drugs and activated with speciﬁ c substances (see 4.3). 
RPMC were incubated for 20 min and HuMC and tissue explant cultures were 
incubated for 1 h before taking samples for histamine analysis. Histamine levels in 
the culture media were measured with a colorimetric ELISA assay (IBL, Hamburg, 
Germany). In experiments where also intracellular histamine levels were measured 
(I), both cells and supernatants were subjected to three freeze thaw cycles to release 
the intracellular histamine from cell samples prior to ELISA-measurements.
To study cytokine secretion, HMC-1 cultures (I) or cultures of synovial tissue 
explants (III, IV) were incubated 20-24 hours after activation. Culture media were 
analysed by colorimetric ELISA-assays for TNF-α (I, III, IV), IL-8 (I), IL-1β (IV) 
IL-1Ra (IV) and VEGF (IV) levels. In experiments where also intracellular TNF-α 
levels were measured (I), both cells and supernatants were subjected to three freeze 
thaw cycles to release the intracellular TNF-α prior to ELISA measurements.
4.5.2 Messenger RNA
Th e level of TNF-α mRNA in HMC-1 cells (I) and the levels of TNF-α, IL-1β and 
VEGF mRNA in synovial tissue (IV) were determined by RT-PCR analysis. 5 x 
106 HMC-1 cells were cultured with or without CMT-3 for 1 h and then activated. 
After 2 h culture, total RNA was isolated with RNeasy columns (I). Synovial mast 
cells were activated with anti-IgE and tissue samples were collected 24 h later. 
Approximately 30 mg synovial tissue was then homogenized and total RNA was 
isolated with RNeasy columns. RNAs were then subjected to reverse transcriptase-
polymerase chain reaction (RT-PCR). Th e PCR products were quantiﬁ ed with a 
GelDoc 2000 system (Bio-Rad).
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4.6 Determination of cell proliferation
4.6.1 Cell numbers
HMC-1 were suspended into fresh supplemented Iscove’s medium to density of 
4 x 105 cells/ml. Cells were counted and cell viability was assessed by trypan blue 
staining on the ﬁ fth day after seeding (II, III). 
mBMMC were cultured in IL-3 or rKL containing media in density of 4 x 105 
cells/ml. Th e cells that were changed from IL-3 media to rKL media were cultured in 
rKL containing media two days before starting the experiment. Cells were counted 
and cell viability was assessed by trypan blue staining on the ﬁ fth day after seeding 
(II, III).
4.6.2 Measurement of [3H]thymidine incorporation
HMC-1 cells (1 x 105) were seeded on a 24-well plate and drugs and 0,5 µCi of 
[3H]thymidine were added to the wells. Cells were harvested 24 hours later on glass 
microﬁ ber ﬁ lters. [3H]thymidine incorporation into cellular DNA, i.e radioactivity 
of the samples, was measured by liquid scintillation counter (II, III). 
4.6.3 BrdU assay
Synovial ﬁ broblasts were trypsinized and 1 x 104 cells were seeded on 96-well plates 
in DMEM. After starving without growth factors for 48 h the cells were cultured 
in DMEM supplemented with 2 % FCS or 50 ng/ml PDGF. When anti-PDGF 
antibodies were used, it was added to culture media 2 h before using the media for 
cells. Imatinib was added into culture media and the plate was incubated in +37 °C. 
After 24 h incubation BrdU substrate was added to the cells and the cellular uptake 
of BrdU was measured colorimetrically 24 h later (V).
4.7 Detection of apoptosis
4.7.1 Cell death detection ELISAplus assay
HMC-1 or mBMMC were seeded into speciﬁ c culture media (see 4.1) to density of 
4 x 105 cells/ml and exposed to drugs for 24 h. Th en the cell fractions were analyzed 
with the Cell death detection ELISAplus assay for internucleosomal degradation of 
genomic DNA typical for apoptosis (II, III). Campthotecin (5 µg/ml) induced cell 
apoptosis was used as a positive control.
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4.7.2 TUNEL labelling
Apoptotic cells were identiﬁ ed by terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labelling (TUNEL) with ApoTag® In Situ Apoptosis Detection kit. 
After 24 h culture with or without CMT-3 (II) or imatinib (III), 2 x 105 HuMCs 
(II, III) or samples of synovial tissue (III) were labelled with digoxigenin-conjugated 
dUTP and terminal deoxyribonucleotide transferase. Th e labelled DNA fragments 
were stained with anti-digoxigenin monoclonal antibody linked with ﬂ uorescein 
and viewed under ﬂ uorescence microscope.
4.8 Analysis of apoptotic mechanism
4.8.1 Measurement of caspase-3, -8 and -9 activity
Th e activities of caspase-3, -8 and -9 in HMC-1 cells (2 x 106) were measured after 6 
h incubation with imatinib (III) or 20 h incubation with CMT-3 (II) by ﬂ uorometric 
(III) or colorimetric (II) activity assays for each speciﬁ c caspase.
4.8.2 Detection of Bcl-2 and Bax
Th e expression of Bcl-2 protein and mRNA of Bcl-2 and Bax were determined in 
HMC-1 (II). Th e cells were cultured in the presence or absence of CMT-3 for 20 h. 
For the western blot analysis the cell pellet was lysed and the protein extracts were 
separated on a 12% SDS-polyacrylamide gel and electroblotted onto a nitrocellulose 
membrane. Th e membranes were incubated with speciﬁ c antibodies against Bcl-2 
and the primary antibodies were detected with horseradish peroxidase (HRP)–
conjugated goat anti-mouse IgG and an enhanced chemiluminecence detection 
system. Th e blots were quantitated with a Gel Doc 2000 system (Bio-Rad). 
To determine the production of Bcl-2 and Bax mRNA in response to CMT-3 
treatment, HMC-1 (5 x 106) cells were treated with CMT-3 for 20 h and thereafter 
total RNA was isolated using RNeasy columns. Bcl-2 and Bax mRNA expression 
was analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR). Primers 
used in PCR are listed in Table 3.
4.9 Immunohistochemistry
4.9.1 Double-labelling immunohistochemistry
Double labelling immunohistochemistry was used to localize TNF-α (III) and IL-
1β (IV) positive cells in RA synovial tissue. Mast cells were identiﬁ ed by staining 
for tryptase using mouse anti-human mast cell tryptase and Mouse Elite Kit or 
Alexa-ﬂ uor (594 or 488) goat anti-mouse antibodies. Macrophages were identiﬁ ed 
by staining for CD68. TNF-α was detected with polyclonal goat antibodies against 
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TNF-α and IL-1β were detected with polyclonal goat antibodies against IL-1β and 
Alexa-ﬂ uor (594) rabbit anti-goat antibodies. Speciﬁ city was controlled by negative 
IgG-control and by omitting the primary antibody.
4.9.2 Thy-1 and CD68
Immunohistochemistry was used to characterise the cultured synovial cells and to 
estimate the amount of contaminating macrophages. Cells (7,5 x 104) were cultured 
on coverslips for 48 h and ﬁ xed with paraformaldehyde (1%) and methanol. Non-
speciﬁ c binding was blocked with 1% milk (Th y-1 staining) or 3 % BSA buﬀ er 
(CD68 staining) before staining the cells with monoclonal antibodies for ﬁ broblast 
speciﬁ c Th y-1 or macrophage speciﬁ c CD68 antibodies. After overnight incubation 
at +4 ºC with the primary antibodies, cells were incubated for 1 h with HRP-
coupled rabbit-anti-mouse antibodies and stained with AEC. Finally, the cells were 
stained with haematoxylin. Speciﬁ city was controlled by negative IgG-control and 
by omitting the primary antibody.
4.10 Studies on PKC activity
We studied the eﬀ ect of CMT-3 on PKC activity in intact HMC-1 cells and in vitro 
with rat brain PKC extract and human recombinant PKC α and δ isoforms (I). 
To examine the eﬀ ect of CMT-3 on the activation of mast cell PKC, we 
determined [3H]phorbol-12,13-dibutyrate binding in intact HMC-1 cells. Th e 
method is based on the binding of phorbol esters only to the membrane-associated, 
activated PKC. HMC-1 cells were treated with CMT-3 for 5 min before PKC 
activation was stimulated with 1 µM of the A23187.
To assay the rat brain PKC activity, brain tissues from 3–4 rats were homogenized 
and eluted through a chromatography column containing DEAE Sephacel (Pharmacia, 
Sweden). Th e human recombinant PKC α and δ isoforms were cloned and expressed 
in baculovirus-infected Sf9 insect cells as described by Tammela et al. (2004). 
Th e kinase activity of PKC was determined by measuring the incorporation 
of 32P from [γ-32P]ATP into PKC-speciﬁ c substrate peptide (FKKSFKL-NH2, 
Chakravarthy et al. 1991). 
4.11 Statistical analysis
Th e results are expressed as mean ± SEM. One-way ANOVA/Tuckey’s test (I, II, V) 
and ANOVA/Dunn´ s test (III) and paired t-test (IV) were used to assess signiﬁ cance 
between controls and treatments. P < 0.05 was considered to be signiﬁ cant.
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5.
RESULTS
In this chapter the results of this thesis are summarised. Th e majority of ﬁ gures is 
presented in the respective original publications I-V.
5.1  CMT-3 inhibits histamine release and cytokine production in 
cultured mast cells (I)
Th e objective of this study was to determine the eﬀ ects of CMT-3 on histamine 
release and on the production of two important cytokines, the proinﬂ ammatory 
TNF-α and the chemotactic IL-8 in cultured mast cells.
CMT-3 inhibited the activation-induced histamine release from cultured rat 
and human mast cells. CMT-3 induced a signiﬁ cant inhibition of compound 48/80-
induced histamine release from RPMC (I, ﬁ gure 1A). Treatment of RPMC with 25 
µM CMT-3 reduced the degranulation percent from 71.7 ± 4.2 % to 28.7 ± 3.4 % 
(p = 0.0013). In HuMCs activated via IgE-receptors, there was a non-signiﬁ cant 
tendency of inhibition by CMT-3 (I, ﬁ gure 1B). 
CMT-3 inhibited PMA-ionophore A23187 -induced TNF-α and IL-8 secretion 
from HMC-1 cells. In the presence of 25 µM CMT-3, the secretion of TNF-α was 
reduced by 86.5 ± 4.1 % (p = 0.00023) in comparison to activated control (I, ﬁ gure 
2A). Similarly, treatment of HMC-1 with 25 µM CMT-3 reduced the IL-8 secretion 
by 90.3 ± 1.1 % (p = 0.00014) in comparison to activated control (I, ﬁ gure 2B).
Th e quantities of intracellular and secreted TNF-α in resting and activated 
HMC-1 cells in the presence of CMT-3 were measured simultaneously and the 
levels of TNF-α mRNA were analysed to determine whether CMT-3 inhibits the 
production and/or the release of TNF-α from the HMC-1 cells. In the presence of 
25 µM CMT-3, a signiﬁ cant decrease in both intracellular and secreted TNF-α 
was evident when compared to the activated control cells (I, ﬁ gure 3). Furthermore, 
25 µM CMT-3 attenuated the activation induced increase in TNF-α mRNA 
expression, although the change was not statistically signiﬁ cant (I, ﬁ gure 4). Th ese 
data strongly indicates that CMT-3 inhibits the production and not just the release 
of TNF-α in HMC-1 cells.
In comparison to doxycycline, CMT-3 was a clearly more potent inhibitor of 
histamine release and cytokine production in mast cells. Doxycycline did not have an 
appreciable eﬀ ect on the histamine release by activated RPMC in the concentration 
range studied (I, ﬁ gure 1A). Doxycycline did inhibit TNF-α and IL-8 secretion (I, 
ﬁ gures 2A and 2B), but less eﬀ ectively than did equimolar concentrations of CMT-3.
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5.2 The activity of PKC is inhibited by CMT-3 (I)
Th is study showed, for the ﬁ rst time, that CMT-3 inhibits the activity of PKC. Th e 
eﬀ ect of CMT-3 on PKC activity was investigated in three diﬀ erent model systems: 
in intact HMC-1 cells, in rat brain homogenate and using human recombinant 
PKC isoforms in Sf9 cells lysates.
First, the eﬀ ect of CMT-3 on [3H]-phorbol 12,13-dibutyrate-binding in intact 
HMC-1 cells stimulated with Ca-ionophore A-23187 was investigated. CMT-3 
decreased the incorporation of [3H]-phorbol 12,13-dibutyrate in a dose-dependent 
manner (I, ﬁ gure 5A). Th is result suggested that CMT-3 might act as a PKC inhibitor. 
Although, recent studies have shown that cells may express also other phorbol ester 
receptors than PKC (Kazanietz 2002), which might inﬂ uence the results.
Th e next step was to determine, whether CMT-3 could inhibit the activity 
of isolated PKC enzymes in vitro. CMT-3 inhibited PKC activity in rat brain 
homogenate, known to be rich in PKC, in a dose-dependent manner with an 
IC50 value of about 30 µM (I, ﬁ gure 5B). CMT-3 was a highly eﬀ ective inhibitor 
in comparison to doxycycline, which did not aﬀ ect the activity of PKC at the 
concentrations studied. Th is is consistent with the ﬁ nding by Webster et al. (1994), 
that doxycycline inhibits PKC activity with clearly higher, pharmacologically 
irrelevant, drug concentrations.
Th e PKC family comprises of at least 12 diﬀ erent isoforms. Since PKC alpha 
and delta are critical PKC isoforms in mast cell function, the eﬀ ect of CMT-3 on 
these isozymes was investigated more closely by using recombinant human PKC 
alpha and delta. CMT-3 inhibited markedly the activities of both PKC alpha and 
PKC delta (I, ﬁ gure 5C). 
5.3  CMTs inhibit proliferation and induce apoptosis of cultured 
mast cells (II)
CMTs are known to induce apoptosis in several malignant cell lines. In this study, 
the ability of four CMTs to inhibit proliferation and induce apoptosis of cultured 
mast cells was investigated.
All studied CMTs reduced signiﬁ cantly the viability of HMC-1 cells (II, ﬁ gure 
1A). In the presence of 25 µM of CMT-3, the number of viable cells decreased 
profoundly during ﬁ ve days of culture (to 12.3 ± 8.0 % of untreated control). CMT-
8 also decreased the viability of HMC-1 cells (to 17.6 ± 0.9 % of untreated control) 
to a similar extent as CMT-3. Moreover, CMT-1 and CMT-308, had a clear eﬀ ect 
on the viability of HMC-1, however, they were less potent than CMT-3 and CMT-
8. Th e antiproliferative eﬀ ect of CMT-3 and CMT-8 was conﬁ rmed by showing 
that CMT-3 also decreased the [3H]thymidine incorporation (II, ﬁ gure 1C). 
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Th e viability of mBMMC can be sustained either by IL-3 or c-kit ligand. To 
assess the dependency of the antiproliferative eﬀ ect of CMT-3 on growth factor, 
mBMMC were cultured in the presence of IL-3 or c-kit-ligand and the eﬀ ects of 
CMT-3, CMT-8 and doxycycline were assessed. In the presence of CMT-3, the 
viability of mBMMC was signiﬁ cantly reduced irrespective whether they were 
cultured in the presence of IL-3 or c-kit-ligand (II, ﬁ gure 2). After ﬁ ve days in 
culture, no living cells could be observed in the presence of 10 µM or 25 µM of 
CMT-3. Similar results were observed for CMT-8. 
Next we studied whether the observed inhibition of viability was due to apoptosis. 
CMTs induced a signiﬁ cant and dose-dependent increase in the amount of apoptotic 
nucleosomes both in HMC-1 cells (II, ﬁ gure 3A) and in mBMMC (II, ﬁ gure 3B). 
In accordance with the proliferation experiments, the eﬀ ect of CMT-8 was in the 
same range while doxycycline was rather ineﬀ ective. Incubation of HuMCs for 24 
h with CMT-3 resulted in a higher number of TUNEL positive HuMCs indicating 
increased rate of apoptosis (II, ﬁ gure 4). Th e ﬁ nding was important as it conﬁ rms 
that also non-malignant human mast cells are prone to CMT-3 induced apoptosis.
When studying the mechanism of apoptosis in HMC-1 cells in response to 
treatment with CMT-3, we observed increases in caspase-3 and caspase-9 activities 
(II, ﬁ gure 5). Furthermore, the protein levels of anti-apoptotic Bcl-2 were decreased 
(to 68.4 ± 16.7% in comparison to control cells (II ﬁ gure 6A) in CMT-3 treated 
HMC-1 cells. Simultaneously, mRNA levels of proapoptotic Bax were increased (to 
145.5 ± 27.0 % in comparison to control cells, II, ﬁ gure 6C), suggesting increased 
rate of Bax synthesis in HMC-1 cells following CMT-3 treatment. However, also 
mRNA levels of Bcl-2 were increased (to 131.0 ± 18.2 % in comparison to control 
cells, II, ﬁ gure 6B), most likely due to a compensatory increase of mRNA expression 
induced by the reduced Bcl-2 protein level.
Th is study showed that CMTs have an antiproliferative and apoptosis-inducing 
eﬀ ect on both malignant and non-malignant mouse and human mast cells. Of 
the studied four chemically modiﬁ ed tetracyclines (CMT-1, CMT–3, CMT-8 and 
CMT-308), CMT-3 was the most potent compound. Doxycycline was relatively 
ineﬀ ective in inhibiting proliferation and inducing apoptosis in mast cells.
5.4  Imatinib induces apoptosis of cultured 
and synovial mast cells (III)
Among a few tyrosine kinases, imatinib inhibits c-kit receptor, which mediates the 
eﬀ ects of SCF, i.e. the most important growth factor for human mast cell viability. 
Th e purpose of this study was to elucidate whether blocking c-kit with imatinib 
induces apoptosis in human mast cells.
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Imatinib exerted a highly antiproliferative eﬀ ect on HMC-1 cells. A profound 
decrease in cell number was observed after 5 days of culture already in the presence 
of 0.1 µM of imatinib and, in the presence of 1 and 10 µM of imatinib, only a few 
living cells were detected after 5 days of culture (III, ﬁ gure 1A). 
To verify that the eﬀ ects of imatinib were mediated via c-kit inhibition, we 
studied mBMMCs, which were cultured in the presence of SCF or IL-3. When the 
mBMMCs were cultured in the presence of SCF and imatinib, there was a strong 
reduction in the cell number at 1 µM and higher imatinib concentrations (III, ﬁ gure 
1B). In contrast, when mBMMCs were cultured in the presence of IL-3, imatinib 
did not signiﬁ cantly reduce the cell number, suggesting that imatinib speciﬁ cally 
aﬀ ected the c-kit-dependent survival pathway. 
Th e observed reduction in HMC-1 cell number was caused by apoptosis as judged 
by typical apoptotic morphology, increased number of apoptotic nucleosomes (III, 
ﬁ gure 1C) and activation of caspase-8 and -9 (III, ﬁ gure 1D). Additional methods to 
detect apoptosis, including annexin binding and TUNEL staining, conﬁ rmed the 
ﬁ nding. Th us, inhibition of c-kit signalling in HMC-1 cells activates a metabolic 
cascade, which induces cell death by apoptosis. 
In HuMCs, cultured in the presence of SCF and an increasing concentration of 
imatinib, a signiﬁ cant increase in the number of apoptotic nucleosomes was observed 
(III, ﬁ gure 2A). Th e induction of human mast cell apoptosis by imatinib was further 
veriﬁ ed by studying nuclear fragmentation (III, insert in ﬁ gure 2A), TUNEL 
staining (III, ﬁ gure 2B), and annexin binding (data not shown). Interestingly, in the 
presence of another supporting cytokine (IL-6), in addition to SCF, human mast 
cells were more resistant to apoptosis (III, ﬁ gure 2A).
In inﬂ amed synovial tissue, there are also other potential cytokine and growth 
factor pathways, in addition to the c-kit pathway, which can support the viability 
of tissue mast cells. Th erefore it was important to study the eﬀ ect of imatinib on 
the viability of tissue mast cells. Culturing rheumatoid synovial tissue explants with 
imatinib induced apoptosis in synovial tissue during 24 h incubation (III, ﬁ gure 
5). Most of the apoptotic cells were mast cells as assessed by double-staining with 
TUNEL and anti-tryptase, and the majority of mast cells in rheumatoid synovial 
tissue were rendered apoptotic during the incubation with imatinib. 
In summary, this study showed that by inhibiting c-kit, imatinib exerts a 
proapoptotic eﬀ ect both on cultured mast cells and, importantly, on mast cells 
resident in RA synovial tissue.
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5.5 Activation of synovial mast cells results in 
production of cytokines (III and IV)
Activated mast cells produce and secrete a remarkable array of proinﬂ ammatory 
mediators. Th e objective of this study was to determine the eﬀ ects of synovial mast 
cell activation on the production of TNF-α, IL-1β, IL-1Ra and VEGF by synovial 
tissue.
Histamine release was determined to verify the activation of synovial mast cells 
(IV, ﬁ gure 1). Anti-IgE induced a signiﬁ cant histamine release from synovial tissue 
explants derived from 12 patients (0.84 ± 0.91 vs. 2.10 ± 1.07 pg/mg wet tissue, p 
= 0.0065) during 1 h culture. Notably, the variation in the basal histamine levels in 
the control tissue cultures was high. However, in each case, except one, addition of 
anti-IgE resulted in histamine release from the explants.
Selective activation of synovial tissue mast cells by anti-IgE induced a highly 
signiﬁ cant increase in the secretion of TNF-α in comparison to untreated control 
(4.56 ± 3.18 vs. 0.49 ± 0.88 pg/mg wet tissue, p = 0.00037) from explants to culture 
media during the 24 h culture (IV, ﬁ gure 2A). Th ese experiments were done with 
synovial tissue from 13 RA patients. Th e main fraction of the secreted TNF-α 
by synovial tissue was shown to be newly synthesized, as no detectable amounts 
of TNF-α were found in tissue culture media samples taken 1 h after mast cell 
activation. Th e data from TNF-α mRNA studies supported this conclusion, as it 
indicated an increased rate of TNF-α synthesis as a result from mast cell activation 
(IV, ﬁ gure 2C). Th e immunohistochemical studies revealed that RA synovial tissue 
contains abundant number of TNF-α positive mast cells (III, ﬁ gure 3).
Activation of mast cells in synovial tissue explants induced a signiﬁ cant increase 
in the secretion of IL-1β in comparison to untreated control (2.55 ± 1.98 vs. 0.058 
± 0.032 pg/mg wet tissue, p = 0.013) during the 24 h incubation (IV, ﬁ gure 3A). 
Synovial tissue from 11 RA patients was used for these experiments. Th e increase 
in IL-1β secretion was most likely due to an increased synthesis rate, as anti-IgE 
induced an elevation in IL-1β mRNA level in synovial tissue (IV, ﬁ gure 3C). 
Immunohistochemical studies showed that when mast cells were activated, a clear 
IL-1β positivity appeared in synovial tissue (IV, ﬁ gure 4). To study in more detail 
which cell types expressed IL-1β, double labelling immunohistochemistry was 
performed. Mainly synovial macrophages were found to be IL-1β positive in tissue 
explants after mast cell activation by anti-IgE. Th ese results indicate that activation 
of mast cells in synovial tissue induces IL-1β expression in synovial macrophages.
Th e untreated control explants of rheumatoid synovial tissue secreted a 
considerable amount of IL-1Ra into tissue culture media (24.0 ± 19.7 pg/mg wet 
tissue, IV, ﬁ gure 5A). Addition of non-speciﬁ c IgG elevated the secretion of IL-1Ra 
to culture media (70.3 ± 20.8 pg/mg wet tissue, p = 0.0006). Yet, the increase in 
the secretion of IL-1Ra was clearly more pronounced in anti-IgE-stimulated samples 
(132.3 ± 17.3 pg/mg wet tissue, p = 0.0000), revealing the involvement of mast-cell-
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dependent component in the secretion of IL-1Ra following addition of anti-IgE. 
Noteworthy, the relative increase of IL-1Ra was clearly smaller than the relative 
increase of IL-1β. Th ese experiments were performed with tissue explants from 7 
RA patients (IV, ﬁ gure 5B).
Th e level of VEGF in tissue culture media 24 h after synovial mast cell activation 
was clearly decreased in comparison to untreated control (5.62 ± 2.3 vs. 8.20 ± 
3.7 pg/mg wet tissue, p = 0.035, IV, ﬁ gure 6A). Th e unexpected decline in VEGF 
was observed consistently in all studied 7 patient samples (IV, ﬁ gure 6B). On the 
contrary, the simultaneous VEGF mRNA expression seemed elevated, although the 
change was not statistically signiﬁ cant. 
In summary, these experiments show that the production of TNF-α and IL-1β 
by RA synovial tissue explants was signiﬁ cantly increased as a result of mast cell 
activation. 
5.6  Imatinib inhibits anti-IgE-induced TNF-α secretion in 
rheumatoid synovial tissue (III)
In the presence of imatinib, the secretion of TNF-α by RA synovial tissue explants 
induced by IgE-dependent activation of mast cells was signiﬁ cantly decreased (III, 
ﬁ gure 4A). However, imatinib did not aﬀ ect acute histamine release by the RA 
synovial tissue (III, ﬁ gure 4B). Th e ﬁ nding was consistent with the observation, that 
imatinib did not have an eﬀ ect on histamine release from cultured mast cells. As 
imatinib was shown to induce apoptosis in synovial mast cells, the observed decrease 
in TNF-α secretion might be due to a decline in the number of viable mast cells in 
tissue explants treated with imatinib.
5.7  CMT-3 inhibits anti-IgE-induced TNF-α and IL-β secretion in 
rheumatoid synovial tissue (unpublished data)
In order to assess the potential beneﬁ ts of CMT-3 in treatment of RA, the eﬀ ects of 
CMT-3 on the secretion of the key cytokines, TNF-α and IL-1β, by RA synovial 
tissue were determined.
Anti-IgE induced histamine release from synovial tissue explants was not aﬀ ected 
by pretreatment with CMT-3 (Figure 7). Th e slight decrease in histamine release by 
25 µM CMT-3 was insigniﬁ cant. Th is result is consistent with the previous ﬁ nding, 
that CMT-3 was rather ineﬀ ective in inhibiting histamine release from HuMC (I).
As shown in Figure 8, CMT-3 decreased signiﬁ cantly the mast cell activation 
induced secretion of TNF-α from RA synovial tissue in comparison to untreated 
tissue explants (2.45 ± 2.14 vs. 5.04 ± 3.23 pg/mg wet tissue, p = 0.001). Th is result 
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Figure 7.  Th e eﬀ ect of CMT-3 on the histamine 
release by synovial tissue explants stimulated 
with anti-IgE. 
 Th e explants were incubated with the indicated 
substances. CMT-3 was added 1 h before 
activation of synovial mast cells with anti-IgE 
and tissue culture media was collected 1 h later. 
Histamine levels in culture media were analyzed 
with ELISA assay. Values of 10 individual patients 
are shown.
Figure 8.  IgE-dependent mast cell activation induces TNF-α secretion from RA 
synovial tissue.
 Th e explants were incubated with the indicated substances. CMT-3 was added 1 h 
before adding anti-immunoglobulins and culture media was collected 24 h later. TNF-
α levels in culture media were analyzed with ELISA assay. A) Means ± SEM and B) 
individual values of 11 diﬀ erent patient samples are shown. ** =p < 0.01
Figure 9.  IgE-dependent mast cell activation induces IL-1β secretion from RA synovial 
tissue. 
 Th e explants were incubated with the indicated substances. CMT-3 was added 1 h 
before adding anti-immunoglobulins and culture media was collected 24 h later. IL-
1Ra levels in culture media were analyzed with ELISA assay. A) Means ± SEM and B) 
individual values of 7 diﬀ erent patient samples are shown. * = p < 0.05
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is in accordance with observations in HMC-1 cells, which showed that CMT-3 
eﬀ ectively inhibits the production of TNF-α in activated mast cells (I).
Figure 9 shows that CMT-3 decreased signiﬁ cantly the mast cell activation 
induced secretion of IL-1β from RA synovial tissue in comparison to untreated 
control explants (1.04 ± 0.51 vs. 1.63 ± 0.60 pg/mg wet tissue, p= 0.025). 
Th ese experiments show that 25 µM CMT-3 is a potent inhibitor of cytokine 
secretion induced by activation of mast cells in RA synovial tissue. If the observed 
inhibitory eﬀ ect could be accomplished in vivo, CMT-3 might possess antirheumatic 
properties.
5.8  Imatinib mesylate inhibits proliferation of rheumatoid synovial 
fi broblasts (V)
Th e exaggerated proliferation of synovial ﬁ broblasts (SFB) is a central feature in the 
development of pannus tissue in RA. As PDGF is an important mitogen for SFB 
and imatinib inhibits the PDGF receptor tyrosine kinase, this study was designed 
to determine the eﬀ ect of imatinib on SFB proliferation. 
PDGF stimulated cultured SFB to proliferate and the addition of 1 µM imatinib 
completely inhibited the PDGF-dependent increase in uptake of BrdU (V, ﬁ gure 
2A). Th e inhibition of PDGF-stimulated proliferation of SFB by imatinib was dose-
dependent in the 0.01–10 µM concentration range. Similar extent of inhibition of 
PDGF-stimulated proliferation was observed when PDGF was neutralized with 
anti-PDGF-antibodies, as compared to inhibition with 1µM imatinib. 
FCS also stimulated the proliferation of SFB. In the presence of imatinib, the 
FCS-stimulated uptake of BrdU was signiﬁ cantly, but not completely reduced (V, 
ﬁ gure 2B). Neutralizing the PDGF in serum by anti-PDGF antibodies also reduced 
the uptake of BrdU by SFB. Th e inhibition of BrdU uptake by 1 µM imatinib was 
comparable to the inhibition observed with anti-PDGF antibodies Furthermore, if 
imatinib was added to media in which PDGF had been neutralized with anti-PDGF 
antibodies, no further inhibition of BrdU uptake was observed. Th ese results suggest 
that imatinib speciﬁ cally prevents the action of PDGF in serum, leaving signalling 
pathways stimulated by other growth factors intact.
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6.
DISCUSSION
In this chapter, the results of the present study are discussed as an entity. A more 
detailed discussion is presented in the original publications I-V.
6.1 Mast cell in synovial infl ammation
Given the increased numbers of mast cells within the inﬂ amed joint and the 
exceptionally wide range of potent mediators secreted by activated mast cells, they 
are likely to contribute the initiation and upholding of chronic inﬂ ammation. 
We used synovial tissue from RA patients to study the consequences of mast cell 
activation in the context of synovitis associated with RA.
Th e rheumatoid synovium, which is relatively easily accessible, is one of the most 
extensively analysed tissue sites of a local immune and inﬂ ammatory reaction. For 
surgical reasons, the rheumatoid tissues examined were derived almost exclusively from 
middle or late stage disease. As the synovial tissue was used for the experiments within 
hours after operation, the prevailing treatments of the patient might have aﬀ ected the 
function of mast cells in the synovial explants. Th us, disease duration, treatments and 
other patient-related data were collected and reported (IV, Table 1).
Mast cell activation may be induced in vivo by several mechanisms. In this study, 
polyclonal anti-human-anti-IgE was used as a mast cell secretagogue as it selectively 
activates mast cells via their FcεRI receptors. It is unlikely that IgE-mediated mast 
cell activation is involved in RA, although IgE rheumatoid factors and immune 
complexes with IgE have been described in small subsets of RA patients (De Clerck 
et al. 1989, Gruber et al. 1988b). In RA, the synovial mast cells could be expected 
to be activated by complement fragments such as C5a, and by immune complexes 
comprised of IgG (Nigrovic and Lee 2005, Benoist and Mathis 2002). Receptors for 
complement fragment C5a are expressed on mast cells in synovium of RA patients 
(Kiener et al. 1998). Yet, in RA synovial tissue a signiﬁ cant proportion of mast cells 
are activated. Th erefore, it is of great importance to study the consequences of mast 
cell activation in synovial tissue, irrespective of the means of activation. Activation 
with anti-IgE provides a reliable means to selectively activate mast cells and to 
study the consequences of their activation in synovial tissue under experimental 
conditions. In future studies, research on the factors which activate human synovial 
mast cells and the consequences of mast cell activation by C5a or immune complexes 
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on cytokine production would be interesting approaches to further clarify the role 
of mast cell activation in RA.
Selective activation of mast cells induced a signiﬁ cant increase in the production 
of TNF-α and IL-1β in rheumatoid synovial tissue explant cultures during the 24 
h culture. We showed that synovial mast cell activation induced IL-1β expression in 
synovial macrophages. One explanatory mechanism behind this observation could 
be that mast-cell-derived TNF-α stimulates synovial macrophages to produce IL-
1β. Synovial macrophages were identiﬁ ed with immunostaining for CD68, which 
is a widely used marker for macrophages. It should be noted that also human mast 
cells have been shown to express CD68 (Nilsson et al. 1996, Horny et al. 1990). If 
these intriquing observations can be veriﬁ ed it could mean that some of the tissue 
cytokine expression attributed in previous studies to macrophages could in fact be 
derived from mast cells. Th erefore it would be of importance in the future to study 
whether also synovial mast cells express CD68. 
In accordance to the present results, Woolley and Tetlow (2000) have shown 
previously by immunohistochemistry that in rheumatoid synovial tissue cytokine 
expression can be observed in the vicinity of mast cells. However, in the cited study 
the authors report that mast cell activation decreased the secretion of TNF-α and 
IL-1β in synovial tissue explants. Th e results of our study contradict these earlier 
ﬁ ndings. We observed a signiﬁ cant and systematic increase in TNF-α and IL-1β 
levels in 13 and 11 patient samples, respectively. Furthermore, the appearance 
of enhanced expression of cytokine mRNA and the appearance of IL-1β protein 
observed by immunohistochemistry as a result of mast cell activation are shown. 
Th ese ﬁ ndings strongly support the concept that mast cell activation indeed results 
in cytokine production in synovial tissue.
We also observed a signiﬁ cant increase in the secretion of anti-inﬂ ammatory IL-
1Ra into the tissue culture media. However, the elevation in IL-1Ra was clearly less 
pronounced that that of IL-1β, i.e. the ratio of IL-1β/IL-1Ra was much lower in the 
culture media of control explant (1/414) than in anti-IgE-treated explant cultures 
(1/52). Less than 5% of IL-1 receptors need to be engaged by IL-1 in order to induce 
a biological response, and it is estimated that a 10- to 100-fold excess of IL-1Ra is 
necessary to achieve a 50% inhibition of the IL-1 response (Arend et al. 1990). Th us 
activation of mast cells in synovial tissue cultures increased the IL-1β/IL-1Ra ratio 
by 8-fold, so favouring a proinﬂ ammatory eﬀ ect.
Several types of cells have been shown to trigger synovial inﬂ ammation. Th e 
autoimmune background of RA emphasizes the role of T cells in the ethiology 
of the disease. However, also mast cells are present in synovium in abundance. 
Th eir capability to secrete an exceptionally wide array of cytokines makes them a 
potential player in the pathophysiology of RA. Th e essential role for mast cells in the 
development of autoantibody-induced arthritis in mice has been recently described 
by Lee et al. (2002). Previous studies on the human synovial mast cell activation 
are limited. Woolley with his colleagues has done fundamental research on the role 
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of mast cells and on the consequences of mast cell activation in RA synovial tissue 
(Bromley et al. 1984, Bromley and Woolley 1984, Tetlow and Woolley 1995a and 
1995b, Tetlow et al. 1998, Woolley and Tetlow 2000). 
Th e present ﬁ ndings extend the earlier knowledge about the role of mast cells in 
RA. We found that mast cell activation results in signiﬁ cant production of TNF-α 
and IL-1β. Several lines of investigation, including experimental and clinical studies, 
have strongly emphasised the importance of these cytokines in the pathogenesis of 
RA (Firestein 2003, Feldmann and Maini 2001, Kay and Calabrese 2004). When 
summarised, our results indicate that mast cells can signiﬁ cantly contribute to the 
pathogenic mechanisms in the synovium that result in erosive arthritis. Th ese data 
also raise the possibility that targeting mast cells in synovial tissue may provide a 
novel strategy for therapeutic intervention in RA.
6.2 CMT-3 and imatinib as inhibitors of mast cell function
Th is study demonstrates that CMT-3 is an eﬀ ective inhibitor of cytokine production 
by mast cells. Th e eﬀ ect of CMT-3 is dose-dependent and signiﬁ cant responses in 
mast cells are evoked with 10–25 µM concentrations. Th e results from analysis 
of intracellular TNF-α levels and TNF-α mRNA expression strongly suggest that 
CMT-3 did not just prevent TNF-α secretion but inhibited the synthesis of TNF-
α. Th is is likely due to inhibition of mast cell activation. Secondly, this study shows 
that CMTs exert an antiproliferative and proapoptotic eﬀ ect on mast cells. Th e 
present results on HMC-1 cells are in accordance with several recent studies, which 
have described that CMTs have antiproliferative activity in several cancer cell lines 
(D’Agostino et al. 2003, Lokeshwar et al. 2002, Tolomeo et al. 2001, Meng et al. 
2000, Seftor et al. 1998). However, the present study is the ﬁ rst to show that CMT-3 
induces apoptosis in non-malignant human immune system cells.
In the ﬁ rst study, which described inhibition of cytokine production in activated 
mast cells by CMT-3, we did not notice signiﬁ cant reduction in cell numbers during 
the 24 h culture period. Nevertheless, according to the results from the second 
study, mast cells are susceptible to CMT-induced apoptosis. Activation of mast cells 
has been shown to protect them from apoptosis by inducing the expression of the 
antiapoptotic molecules (Xiang et al. 2001, Möller et al. 2003). Th is could explain 
the contrasting results of our two studies concerning the cell numbers. Th is would 
also mean, that mast cells which are most likely in activated state in inﬂ amed tissues, 
would be less prone to CMT-induced apoptosis. Additionally, in the second study 
the decrease in cell numbers was observed after 5 days of culturing with CMT-3, 
while the cytokine production was measured after 24 h of culturing with CMT-3. 
Related to the study II, we observed also that the cell numbers were not signiﬁ cantly 
decreased after 24 h (unpublished data), although the signs of apoptosis, such as 
apoptotic nucleosomes and caspase activity, were detectable. Th erefore, on the basis 
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of these studies, the possibility remains that at least part of the observed inhibition of 
cytokine production by CMT-3 is caused by the induction of mast cell apoptosis.
So far there have been only limited number of means to selectively inhibit 
mast cell functions. SCF critically regulates the migration and survival of mast cell 
precursors, promotes the proliferation of both immature and mature mast cells, 
enhances mast cell maturation, directly induces secretion of mast cell mediators, 
and regulates the extent of mediator release in mast cells activated by IgE-dependent 
mechanisms (Galli et al. 1993). With this background, it was rather predictable that 
imatinib, given its capacity to inhibit c-kit, the receptor of SCF, would have profound 
eﬀ ects on mast cell function. Th is study showed that imatinib indeed is an eﬀ ective 
inhibitor of mast cell viability within concentrations that are pharmacologically 
relevant (0.1–1 µM). Imatinib now provides a new interesting tool for the research 
of mast cell biology and to study the role of mast cells in diﬀ erent physiological 
and pathological conditions. Th e selectivity of imatinib towards only a few tyrosine 
kinases, in this case c-kit, makes it an attractive means to study mast cells. Th e 
observed proapoptotic eﬀ ect of imatinib in rheumatoid synovium is in all likelihood 
relatively mast-cell speciﬁ c, as in RA synovium c-kit is expressed exclusively by mast 
cells (Ceponis et al. 1998). As imatinib is already approved for use in humans and 
the safety proﬁ le of the drug is known (Savage and Antman 2002), the applications 
of basic research ﬁ ndings to clinical practise might be facilitated. 
In these experiments, several mast cell models were used. HMC-1 is a malignant 
human mast cell line. Th e use of HMC-1 cells provides an easily accessible model 
of proliferating mast cells that have also the capability to secrete cytokines Th e lack 
of functional FcεRI-receptors is the major limitation of HMC-1 model. Human 
CD34+ stem cell derived mast cells (HuMCs) are at the moment the best in vitro 
model for human mast cells. Th ese cells can be activated via their FcεRI-receptors 
and their phenotype is close to human MCTC-type mast cells. Th e time-consuming 
and expensive maturation process of CD34+ stem cells to mast cells limits the use 
of this model. In the present work, rodent mast cells were used as additional mast 
cell models in early screening of drug eﬀ ects. RPMC is the most extensively studied 
mast cell model in the context of histamine release. mBMMC are primary mast cells 
that proliferate. mBMMC provides a means to study the eﬀ ect of diﬀ erent growth 
factors on the proliferation.
In conclusion, both CMT-3 and imatinib were found to induce apoptosis in 
mast cells. Th eir mechanism of action diﬀ ers most likely. Of these two compounds, 
imatinib probably provides relative selectivity against mast cells, while CMT-3 is 
likely to aﬀ ect other cell types as well as mast cells. However, both compounds 
eﬀ ectively inhibit mast cell functions and thus CMT-3 and especially imatinib 
could be used as novel drugs to inhibit mast cells.
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6.3 PKC inhibition as a target for CMT-3
Protein kinase C comprises a family of enzymes implicated in cellular diﬀ erentiation, 
growth control and tumour promotion. In this study we show, for the ﬁ rst time, that 
CMT-3 inhibits PKC activity. Of the several PKC isoenzymes, at least PKC alfa and 
PKC delta are inhibited by CMT-3 is evident. Considering the central role of PKC 
in numerous cellular processes, the observed capacity to inhibit PKC might open 
new perspectives for the clinical use of CMT-3.
Th e observed inhibitory eﬀ ects of CMT-3 on mast cell function could 
be explained, at least partially, by the inhibition of PKC. PKC is expressed in 
diﬀ erent types of mast cells and it is required for both early and delayed responses 
(Nechushtan and Razin 2001). Of the diﬀ erent PKC isoforms, at least alpha, beta, 
delta, epsilon and theta are expressed in a rat mast cell line (Nechushtan and Razin 
2001). In addition to PKC alpha and PKC delta, also PKC beta is implicated in 
the mast cell activation and it would have been rational to determine the eﬀ ect of 
CMT-3 on this isoform as well. Unfortunately, PKC beta isoform was not available 
for this study. Th e pathways activated following crosslinking of FcεRI have been 
extensively studied and it is clear that PKC is involved in the cascade (Tsaczyk and 
Gilﬁ llan 2001, Turner and Kinet 1999). Based on this, PKC is acknowledged as 
one attractive target for interfering the mast cell activation. Consistent with this, 
selective PKC inhibitors have been shown to block FcεRI-dependent mediator 
release of human mast cells (Noll et al. 1997, Amon et al. 1996, Kimata et al. 1999 
and 2000). However, the precise targets for the PKC signals within the secretory 
machinery in mast cells are not known. 
Whether the mechanism underlying the ability of CMT-3 to induce apoptosis 
in mast cells, is PKC inhibition or not, remains unclear. Th e previous ﬁ ndings on 
the role of PKC in mast cell apoptosis are somewhat contradictory. An enhanced 
proliferation rate in a rat mast cell line overexpressing PKC has been described 
(Chang et al. 1997), although PKC has been shown to play an inhibitory role in IL-
3-mediated mouse mast cell proliferation (Chaikin et al. 1990, Baranes and Razin 
1991).
PKC is central in signalling pathways involved in adaptive immune responses in 
mammals. PKC is known to regulate B cell activation and survival (Saijo et al. 2003) 
and PKC activation induces T cell proliferation and activation (Berry and Nishizuka 
1990, Isakov and Altman 2002, Wilkinson and Nixon 1998). Considering the central 
role of T and B cells in pathoimmunological processes, PKC might oﬀ er a potential 
target to control autoimmune diseases. Th ere is evidence from animal models that 
selective inhibitors of protein kinase C are useful in the treatment of adjuvant-
induced arthritis (Birchall et al. 1994, Zhou et al. 1999). Given the autoimmune 
background of RA, CMT-3, besides inhibiting the cytokine production induced by 
mast cell activation in rheumatoid synovium, could be beneﬁ cial in treatment of RA 
as it could reduce the T and B cell driven processes by inhibiting PKC. 
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In addition to RA and other diseases associated with inappropriate mast cell 
activation, PKC inhibition has several other clinical implications, especially in 
oncology (Hofmann 2004, Lahn et al. 2004, Poole et al. 2004). Th e ability of 
CMT-3 to inhibit PKC activity might be a contributing factor in the recognized 
anticancer activity of CMT-3.
6.4 Prospective antirheumatic effect of CMT-3
Tetracyclines have been studied in the context of RA because of their anti-
inﬂ ammatory properties and particularly because of their capability to inhibit MMPs 
(Greenwald 1994). A meta-analysis of the clinical trials on the use of tetracyclines 
in RA found that tetracyclines, in particular minocycline, are associated with a 
clinically signiﬁ cant improvement in disease activity in RA (Stone et al. 2003). 
However, contrasting results have also been obtained (van den Laan et al. 2001). 
Nevertheless, the studies share the conclusion that tetracyclines appear not to aﬀ ect 
the radiological progression of the disease. In contrast, CMT-3 has been reported to 
have beneﬁ cial eﬀ ect on the bone mass and bone integrity in arthritic rats (Zernicke 
et al. 1997).
Inhibition of structural damage is a primary therapeutic aim in RA. MMPs form 
a family of enzymes with a major a role in cartilage destruction associated with RA. 
Results from clinical trials with MMP inhibitors in RA have been unequivocal, with 
some studies being terminated because of lack of eﬃ  cacy or safety concerns (Keystone 
2004). Nevertheless, this approach has been considered promising (Martel-Pellertier 
et al. 2001, Elliot and Cawston 2001). Several studies have conﬁ rmed that CMT-3 is 
a potent inhibitor of several MMPs, with speciﬁ city towards the MMP-2, MMP-9, 
and MMP-14 isozymes (Acharya et al. 2004). All of these have been found to be 
overexpressed in RA synovium (Konttinen et al. 1999). In addition to inhibiting MMP 
activity, CMT-3 has been shown to induce apoptosis in human osteoclasts, which 
might contribute to its antiresorptive action in bone (Holmes et al. 2004). Moreover, 
CMT-3 was found to inhibit SFB invasion in an experimental animal model (Seftor 
et al. 1998). Taken together, preventing tissue destruction could be one dimension in 
the potential antirheumatic eﬀ ect of CMT-3 (Sorsa et al. 1998). 
Th e present study showed that CMT-3 inhibits eﬀ ectively cytokine production 
in activated mast cells and in human synovial tissue stimulated with selective mast 
cell secretagogue. Th e inhibition of TNF-α and IL-1β production in synovial 
tissue might be a remarkable ﬁ nding considering the antirheumatic potential of 
CMT-3. Th e previous observation, that CMT-3 eﬀ ectively blocks PGE2 production 
in chondrocytes and macrophages (Patel et al. 1999), strengthens the concept of 
CMT-3 as an anti-inﬂ ammatory agent in RA. Besides joint destruction and chronic 
inﬂ ammation, one prominent feature of RA is angiogenesis. CMT-3 has been 
shown to inhibit angiogenesis in vitro (Fife et al. 2000). Th is character of CMT-3 
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is believed to be important considering the anticancer activity, but it could also be 
beneﬁ cial in the treatment of RA.
Laroux et al. (1999) studied the eﬀ ect of CMT-3 in a model of chronic polyarthritis 
in mice in which the arthritis was induced with monoclonal antibodies. Th ey found 
that CMT-3 could possess beneﬁ cial activity in arthritis. In another study, Zernicke 
et al. (1997) detected positive eﬀ ects by CMT-3 and CMT-8 on the amount of bone 
and the biomechanical properties of femoral neck in rat adjuvant arthritis. However, 
Zernicke et al. (1997) did not observe any anti-inﬂ ammatory eﬀ ects in this arthritis 
model following CMT-3 treatment. 
In summary, in vitro CMT-3 exerts several interesting properties, such as 
inhibition of MMPs, inhibition of cytokine and prostaglandin production, 
inhibition of osteoclast activity and inhibition of angiogenesis, which suggest eﬃ  cacy 
in the treatment of RA. Based on the results of the present study and previous 
publications, further studies are warranted to evaluate the true potential of CMT-3 
as an antirheumatic agent.
6.5 Imatinib as a novel antirheumatic drug
At present imatinib is approved for treatment of chronic myeloid leukemia and 
gastrointestinal stromal tumours. Th e unique mechanism of action and the 
relatively high selectivity of imatinib have also evoked interests concerning many 
other diseases, including RA. GIST-patient suﬀ ering also from RA was treated 
with imatinib at Helsinki University Central Hospital and an improvement in RA 
symptoms was observed during the treatment. Th is observation gave rationale to a 
12 weeks pilot clinical study, which demonstrated a clinical improvement in three 
RA patients with active disease that had been resistant to earlier therapies (Eklund 
and Joensuu 2003). A case report, published by Miyachi et al. (2003), describes a 
similar ﬁ nding. A single patient suﬀ ering from severe RA has been treated with 
imatinib for nearly 3 years at Helsinki University Central Hospital. Th e activity 
of RA was very low during the entire treatment period (unpublished data). Th ese 
ﬁ ndings, although based on a very small patient population, suggest that imatinib 
might have signiﬁ cant antirheumatic activity. 
Mast cells express c-kit (Tsai et al. 1991, Kirshenbaum et al. 1992) and synovial 
ﬁ broblasts express PDFGR (Butler et al. 1989, Heldin and Westermark 1999), both 
of which are inhibited by imatinib. In addition to mast cell maturation and viability, 
c-kit tyrosine kinase receptor also links to degranulation of mast cells (Galli 1993). 
Th e present study showed that proliferation of cultured and synovial mast cells was 
inhibited by imatinib and the inhibitory eﬀ ect was c-kit dependent. Th is study 
showed that the proliferation of synovial ﬁ broblasts was inhibited by imatinib 
through the inhibition of PDGF-mediated signalling. As mast cells are involved 
in many aspects of the inﬂ ammatory reaction characteristic for RA (Nigrovic and 
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Lee 2005), the mast cell apoptosis in synovium could alleviate the inﬂ ammatory 
reaction. Th e proapoptotic eﬀ ect of imatinib was attributed to its capacity to inhibit 
c-kit receptors on mast cells. Supporting this concept, mast-cell-activation-induced 
TNF-α secretion by synovial tissue explants was found to be inhibited by imatinib. 
Imatinib also inhibited proliferation of synovial ﬁ broblasts stimulated by PDGF or 
serum. Typical features of RA SFB are enhanced production of matrix-degrading 
enzymes and cytokines and an excessive and invasive growth. As synovial ﬁ broblasts 
are one central cell type directly contributing to joint destruction, the inhibition 
of SFB proliferation by imatinib may be beneﬁ cial in RA and may result in an 
antirheumatic eﬀ ect. Next, it would be of interest to study the eﬀ ects of imatinib on 
the MMP and cytokine production in SFB.
Th e synergistic inhibitory eﬀ ect of imatinib on two types of synovial cells 
involved in the pathogenesis of RA, may well explain the recent clinical observations 
of antirheumatic activity of imatinib. However, a recent research paper describes and 
intriquing ﬁ nding that imatinib inhibits also the M-CSF receptor, c-fms (Dewar et 
al. 2005). M-CSF appears to be central in the local activation, recruitment and 
survival of macrophage lineage cells at the site of inﬂ ammation (Hamilton 2002). 
Th us, M-CSF has been proposed as a potential factor for inhibition in order to yield 
an anti-inﬂ ammatory eﬀ ect (Hamilton 2002). Th us, the capacity of imatinib to 
inhibit M-CSF receptor c-fms might also play a role in the possible antirheumatic 
activity.
A possible future approach to further elucidate the role of mast cells in RA could 
be the use of more selective c-kit inhibitors, which would leave the other members of 
the type III receptor tyrosine kinase family intact. Th e increased selectivity would 
most likely result in fewer side eﬀ ects. However, it is impossible to predict whether 
the inhibition of c-kit would be suﬃ  cient to produce an antirheumatic eﬀ ect as 
the inhibition of both PDGFR and c-fms potentially results in further beneﬁ ts in 
treatment of RA, as discussed above.
In conclusion, results from preliminary clinical trials on the eﬃ  cacy of imatinib 
in the treatment of RA are promising (Eklund and Joensuu 2003, Miyachi et al. 
2003). Th e present study could, at least partially, provide a basis for the observed 
antirheumatic activity of imatinib. However, it remains to be seen whether the 
antirheumatic activity of imatinib can be conﬁ rmed in future clinical trials.
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7.
SUMMARY AND CONCLUSIONS
In order to develop new therapies for RA, it is essential to increase the understanding 
of the mechanisms that contribute to the disease process. As RA is a chronic 
inﬂ ammatory disease of the joints, inﬂ ammatory mediators play an important 
role in the development of the disease. Several lines of evidence have indicated the 
involvement of mast cells in the pathogenesis of RA. One of the main ﬁ ndings of 
this study was that selective IgE-dependent activation of synovial mast cells results 
in production of two key cytokines, TNF-α and IL-1β, in rheumatoid synovial 
tissue explants. An increase in the secretion of anti-inﬂ ammatory IL-1Ra was also 
seen in response to synovial mast cell activation, but the relative increase in IL-1Ra 
was clearly smaller than that of IL-1β. Th us, mast cell activation was shown to be 
capable of contributing to the cytokine excess characteristic for RA and to shift the 
cytokine balance towards proinﬂ ammatory state. Based on the results of this study 
and previous ﬁ ndings by others, mast cells presumably play a role in the pathogenesis 
of RA. Th us mast cells can be seen as a potential target for antirheumatic therapy. 
Th is study showed that imatinib and CMT-3 may represent novel compounds to 
inhibit mast cell function. Imatinib exerts a strong proapoptotic eﬀ ect on cultured 
human mast cells and, importantly, on human synovial mast cells. Th e mechanism 
of action was attributed to the inhibition of the mast cell growth factor receptor c-
kit. CMT-3 potently inhibits mast cell activation and cytokine production by mast 
cells, possibly by inhibiting PKC. CMT-3 induces also apoptosis in cultured mouse 
and human mast cells. Based on the results of this study and the previous ﬁ ndings, 
it can be concluded that further studies are warranted to determine the possible 
therapeutic eﬃ  cacy of CMT-3 in arthritis
Destruction of the articular structures is a prominent feature of RA and it is 
pivotal in the development of disability. Synovial ﬁ broblasts are the main eﬀ ector 
cells in the joint destruction in RA, but they also contribute to the inﬂ ammatory 
process. Th ese features of rheumatoid synovial ﬁ broblasts make them an attractive 
target for antirheumatic therapy. Th is study showed that imatinib inhibits PDGF-
stimulated proliferation of rheumatoid synovial ﬁ broblasts, which might contribute 
to its antirheumatic eﬀ ects. 
Currently available DMARDs are limited by their ability to achieve early 
and sustained response, by their cumulative toxicity and by the lack of long-term 
remissions. Th e new biological therapies have greatly improved the treatment of severe 
RA. However, the biological drugs are extremely expensive, long-term remissions 
during the treatments are rare, and the disease tends to ﬂ are when the treatments 
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are discontinued. Furthermore, a signiﬁ cant proportion of patients fail to respond to 
these therapies, suggesting that additional important pathophysiological mechanisms 
may exist. Th is also reﬂ ects the need for new drug innovations for the treatment of 
the patients who do not beneﬁ t from current therapies. Imatinib represents one 
potential novel approach as it may exert antirheumatic activity by inhibiting mast 
cell activity and proliferation of synovial ﬁ broblasts in rheumatoid synovium. Th e 
preliminar clinical ﬁ ndings on the eﬃ  cacy of imatinib in the treatment of RA are 
consistent with this conclusion. Th us, imatinib could oﬀ er a new treatment strategy 
for those patients who fail the current antirheumatic therapy. Future clinical trials 
are needed to evaluate whether this approach is feasible.
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